Elite Pharmaceuticals (ELTP) 10-Q 10 Feb 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2019	Feb. 04, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	ELITE PHARMACEUTICALS INC /NV/
Entity Central Index Key	0001053369
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		839,190,670
Entity Incorporation State Country Code	NV
Entity File Number	001-15697
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Current assets:
Cash	$ 1,870,080	$ 2,277,643
Accounts receivable, net of allowance for doubtful accounts of $-0-, respectively	2,565,323	1,321,805
Inventory	3,810,401	4,515,723
Prepaid expenses and other current assets	796,496	741,371
Total current assets	9,042,300	8,856,542
Property and equipment, net of accumulated depreciation of $10,634,174 and $9,651,718, respectively	7,519,003	8,443,849
Intangible assets, net of accumulated amortization of $-0-, respectively	6,634,035	6,634,035
Operating lease - right to use asset	412,063
Other assets:
Restricted cash - debt service for NJEDA bonds	403,575	398,125
Security deposits	75,534	69,383
Total other assets	479,109	467,508
Total assets	24,086,510	24,401,934
Current liabilities:
Accounts payable	986,016	1,375,347
Accrued expenses	4,423,761	3,713,601
Deferred revenue, current portion	430,000	1,013,333
Bonds payable, current portion, net of bond issuance costs	90,822	80,822
Loans payable, current portion	356,137	573,029
Lease obligation - operating lease	203,984
Customer deposits	55,652	150,000
Senior secured promissory note - related party	1,200,000
Total current liabilities	7,746,372	6,906,132
Long-term liabilities:
Deferred revenue, net of current portion	62,224	238,890
Bonds payable, net of current portion and bond issuance costs	1,332,945	1,427,315
Senior secured promissory note - related party		1,200,000
Loans payable, net current portion	530,480	699,269
Lease obligation - operating lease, net of current portion	221,166
Derivative financial instruments - warrants	5,078,525	2,487,830
Other long-term liabilities	34,916	46,402
Total long-term liabilities	7,260,256	6,099,706
Total liabilities	15,006,628	13,005,838
Mezzanine equity
Series J convertible preferred stock; par value $0.01; 50 shares authorized, 24.0344 issued and outstanding as of March 31, 2019		13,903,960
Shareholders' equity (deficit):
Series J convertible preferred stock; par value of $0.01; 50 shares authorized; 24.0344 issued and outstanding as of December 31, 2019	13,903,960
Common stock; par value $0.001; 1,445,000,000 shares authorized,; 833,953,570 shares issued and 833,853,570 outstanding as of December 31, 2019; 995,000,000 shares authorized, 824,946,559 shares issued and 824,846,559 shares outstanding as of March 31, 2019	833,956	824,949
Additional paid-in capital	149,631,585	148,780,087
Treasury stock; 100,000 shares as of December 31, 2019 and March 31, 2019; at cost	(306,841)	(306,841)
Accumulated deficit	(154,982,778)	(151,806,059)
Total shareholders' equity (deficit)	9,079,882	(2,507,864)
Total liabilities, mezzanine equity and shareholders' equity (deficit)	$ 24,086,510	$ 24,401,934

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable, current	$ 0	$ 0
Accumulated depreciation	10,634,174	9,651,718
Accumulated amortization on intangible assets
Temporary equity, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,445,000,000	995,000,000
Common stock, shares issued	833,953,570	824,946,559
Common stock, shares outstanding	833,853,570	824,846,559
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	50	50
Preferred stock, shares issued	24.0344	24.0344
Preferred stock, shares outstanding	24.0344	24.0344
Treasury stock, shares	100,000	100,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Manufacturing fees	$ 3,754,721	$ 2,108,487	$ 10,851,425	$ 4,456,832
Licensing fees	1,300,392	585,479	2,197,915	1,767,881
Total revenue	5,055,113	2,693,966	13,049,340	6,224,713
Cost of revenue	2,163,376	1,771,136	7,529,918	3,890,086
Gross profit	2,891,737	922,830	5,519,422	2,334,627
Operating expenses:
Research and development	986,832	2,454,098	3,032,357	6,236,192
General and administrative	878,540	748,151	2,358,588	2,245,900
Non-cash compensation through issuance of stock options	11,802	36,547	53,518	109,641
Depreciation and amortization	323,368	321,164	986,001	891,390
Total operating expenses	2,200,542	3,559,960	6,430,464	9,483,123
Income (loss) from operations	691,195	(2,637,130)	(911,042)	(7,148,496)
Other (expense) income:
Interest expense	(94,514)	(89,897)	(283,649)	(279,037)
Change in fair value of derivative instruments - warrants	(3,059,695)	380,976	(2,590,695)	807,347
Proceeds from sale of ANDAs	600,000		600,000
Interest income	2,334	1,733	10,667	4,570
Other (expense) income, net	(2,551,875)	292,812	(2,263,677)	532,880
Loss from operations before income tax	(1,860,680)	(2,344,318)	(3,174,719)	(6,615,616)
Income tax provision			(2,000)
Net loss attributable to common shareholders	$ (1,860,680)	$ (2,344,318)	$ (3,176,719)	$ (6,615,616)
Basic net loss per share attributable to common shareholders	$ 0	$ 0	$ 0	$ (0.01)
Diluted net loss per share attributable to common shareholders	$ 0	$ 0	$ 0	$ (0.01)
Basic weighted average Common Stock outstanding	829,394,203	819,412,807	828,466,951	811,603,678
Diluted weighted average Common Stock outstanding	829,394,203	819,468,881	828,466,951	811,659,752

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Series J Preferred Stock	Common Stock	Additional Paid-In Capital	Treasury Stock	Accumulated Deficit	Total
Balance at Mar. 31, 2018		$ 802,629	$ 146,602,502	$ (306,841)	$ (142,526,738)	$ 4,571,552
Balance, Shares at Mar. 31, 2018		802,626,761		100,000
Net loss					(1,687,766)	(1,687,766)
Common Stock sold pursuant to the Lincoln Park purchase agreement		$ 2,000	166,170			168,170
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares		2,000,000
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement		$ 23	2,161			2,184
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares		23,297
Costs associated with raising capital			(2,161)			(2,161)
Non-cash compensation through the issuance of employee stock options			36,549			36,549
Balance at Jun. 30, 2018		$ 804,652	146,805,221	$ (306,841)	(144,214,504)	3,088,528
Balance, Shares at Jun. 30, 2018		804,650,058		100,000
Net loss					(2,583,532)	(2,583,532)
Common Stock sold pursuant to the Lincoln Park purchase agreement		$ 12,142	1,215,972			1,228,114
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares		12,142,083
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement		$ 171	17,962			18,133
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares		170,108
Costs associated with raising capital			(18,160)			(18,160)
Non-cash compensation through the issuance of employee stock options			36,545			36,545
Balance at Sep. 30, 2018		$ 816,965	148,057,540	$ (306,841)	(146,798,036)	1,769,628
Balance, Shares at Sep. 30, 2018		816,962,249		100,000
Net loss					(2,583,532)	(2,583,532)
Common Stock sold pursuant to the Lincoln Park purchase agreement		$ 3,500	270,045			273,545
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares		3,500,000
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement		$ 37	3,099			3,136
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares		37,890
Costs associated with raising capital			(3,132)			(3,132)
Non-cash compensation through the issuance of employee stock options			36,547			36,547
Balance at Dec. 31, 2018		$ 820,502	14,836,099	$ (306,841)	(149,142,354)	(264,594)
Balance, Shares at Dec. 31, 2018		820,500,139		100,000
Balance at Mar. 31, 2019		$ 824,949	148,780,087	$ (306,841)	(151,806,059)	(2,507,864)
Balance, Shares at Mar. 31, 2019		824,946,559		100,000
Net loss					279,702	279,702
Common Stock sold pursuant to the Lincoln Park purchase agreement		$ 4,000	336,300			340,300
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares		4,000,000
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement		$ 47	4,153			4,200
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares		47,136
Costs associated with raising capital			(4,200)			(4,200)
Non-cash compensation through the issuance of employee stock options			26,194			26,194
Balance at Jun. 30, 2019		$ 828,996	149,142,534	$ (306,841)	(151,526,357)	(1,861,668)
Balance, Shares at Jun. 30, 2019		828,993,695		100,000
Net loss					(1,595,741)	(1,595,741)
Common Stock sold pursuant to the Lincoln Park purchase agreement		$ 3,895	379,692			383,587
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares		3,895,233
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement		$ 53	5,915			5,968
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares		53,132
Costs associated with raising capital			(5,968)			(5,968)
Non-cash compensation through the issuance of employee stock options			15,522			15,522
Balance at Sep. 30, 2019		$ 832,944	149,537,695	$ (306,841)	(153,122,098)	(3,058,300)
Balance, Shares at Sep. 30, 2019		832,942,060		100,000
Net loss					(1,860,680)	(1,860,680)
Common Stock sold pursuant to the Lincoln Park purchase agreement		$ 1,000	82,100			83,100
Common Stock sold pursuant to the Lincoln Park purchase agreement, Shares		1,000,000
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement		$ 12	1,030			1,042
Common Stock issued as additional commitment shares pursuant to the LPC purchase agreement, Shares		11,510
Costs associated with raising capital			(1,042)			(1,042)
Non-cash compensation through the issuance of employee stock options			11,802			11,802
Reclassification of mezzanine equity to permanent equity	$ 13,903,960					13,903,960
Reclassification of mezzanine equity to permanent equity, shares	24
Balance at Dec. 31, 2019	$ 13,903,960	$ 833,956	$ 149,631,585	$ (306,841)	$ (154,982,778)	$ 9,079,882
Balance, Shares at Dec. 31, 2019	24	833,953,570		100,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,176,719)	$ (6,615,616)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	993,086	941,814
Amortization of operating leases - right to use assets	(142,025)
Change in fair value of derivative financial instruments - warrants	2,590,695	(807,347)
Non-cash compensation accrued	723,720	1,365,000
Non-cash compensation through the issuance of employee stock options	53,518	109,641
Non-cash rent expense and lease accretion	1,555	4,738
Change in operating assets and liabilities:
Accounts receivable	(1,243,518)	15,436
Inventory	705,322	705,616
Prepaid expenses and other current assets	21,849	(144,849)
Accounts payable, accrued expenses and other current liabilities	(402,759)	528,805
Deferred revenue and customer deposits	(854,368)	(760,000)
Lease obligations - operating leases	141,960
Net cash used in operating activities	(587,684)	(4,656,762)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(3,148)	(19,130)
Net cash used in investing activities	(3,148)	(19,130)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of stock	806,987	1,669,829
Payment of bond principal	(95,000)	(90,000)
Other loan payments	(523,268)	(398,046)
Net cash provided by financing activities	188,719	1,181,783
Net change in cash and restricted cash	(402,113)	(3,494,109)
Cash and restricted cash, beginning of period	2,675,768	7,570,803
Cash and restricted cash, end of period	2,273,655	4,076,694
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest	168,560	151,754
Financing of equipment purchases and insurance renewal	54,462	477,116
Commitment shares issued to Lincoln Park Capital	11,098	23,453
Supplemental non-cash amounts of lease liabilities arising from obtaining right of use assets	$ 554,088

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview Elite Pharmaceuticals, Inc. (the "Company" or "Elite") was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary Elite Laboratories, Inc. ("Elite Labs") which was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. Elite Labs engages primarily in researching, developing and licensing proprietary orally administered, controlled-release drug delivery systems and products with abuse deterrent capabilities and the manufacture of generic, oral dose pharmaceuticals. The Company is equipped to manufacture controlled-release products on a contract basis for third parties and itself, if and when the products are approved. These products include drugs that cover therapeutic areas for pain, allergy, bariatric and infection. Research and development activities are done so with an objective of developing products that will secure marketing approvals from the United States Food and Drug Administration ("FDA"), and thereafter, commercially exploiting such products. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission ("SEC"). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Elite Laboratories, Inc. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, which are, in the opinion of management, necessary for a fair presentation of such statements. The results of operations for the three and nine months ended December 31, 2019 are not necessarily indicative of the results that may be expected for the entire year. Going Concern At December 31, 2019, the Company had unrestricted cash balances totaling $1,870,080. The Company has incurred losses and negative cash flows from operations, including operating income of $691,195 and loss of $2,637,130 for the three months ended December 31, 2019 and 2018, and operating losses of $911,042 and $7,148,496 for the nine months ended December 31, 2019 and 2018, respectively. In addition, overall working capital, defined as current assets minus current liabilities decreased by $654,482 as of December 31, 2019. Based on the foregoing, the Company has determined that there did appear to be evidence of substantial doubt of its ability to continue as a going concern. To continue as a going concern, the Company will need to do some or all of the following, without limitation: obtain additional financing, increase sales of existing products, bring additional products in the pipeline to market and/or reduce expenses. The successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements included herein do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Segment Information Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC 280"), Segment Reporting The Company has determined that its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Applications ("ANDA") and products whose marketing approvals were secured via a New Drug Application ("NDA"). ANDA products are referred to as generic pharmaceuticals and NDA products are referred to as branded pharmaceuticals. There are currently no intersegment revenues. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company's unaudited condensed consolidated financial statements. Please see Note 15 for further details. Revenue Recognition The Company generates revenue from the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, commercialization of products either by license and the collection of royalties, or through the manufacture of formulations and the development of new products and the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations. The Company also generates revenue through its focus on the development of various types of drug products, including branded drug products which require NDAs. Under ASC 606, Revenue from Contacts with Customers Nature of goods and services The following is a description of the Company's goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable: a) Manufacturing Fees The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if, and when, the products are approved. These products include products using controlled-release drug technology and products utilizing abuse deterrent technologies. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release and abuse deterrent pharmaceutical products. The Company recognizes revenue when the customer obtains control of the Company's product based on the contractual shipping terms of the contract. Revenue on product are presented gross because the Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. b) License Fees The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company's contracts contained a significant financing component as of December 31, 2019. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer's products occurs. Disaggregation of revenue In the following table, revenue is disaggregated by type of revenue generated by the Company and timing of revenue recognition. The table also includes a reconciliation of the disaggregated revenue with the reportable segments: For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 NDA: Licensing fees $ 250,000 $ 250,000 $ 750,000 $ 750,000 Total NDA revenue 250,000 250,000 750,000 750,000 ANDA: Manufacturing fees $ 3,754,721 $ 2,108,487 $ 10,851,425 $ 4,456,832 Licensing fees 1,050,392 335,479 1,447,915 1,017,881 Total ANDA revenue 4,805,113 2,443,966 12,299,340 5,474,713 Total revenue $ 5,055,113 $ 2,693,966 $ 13,049,340 $ 6,224,713 Collaborative Arrangements Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808, Collaborative Arrangements ● The parties to the contract must actively participate in the joint operating activity; and, ● The joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. The Company entered into a sales and distribution licensing agreement with Epic Pharma LLC, ("Epic") dated June 4, 2015 (the "2015 Epic License Agreement"), which has been determined to satisfy the criteria for consideration as a collaborative agreement, and is accounted for accordingly, in accordance with GAAP. The Company entered into a Master Development and License Agreement with SunGen Pharma LLC dated August 24, 2016 (the "SunGen Agreement"), which has been determined to satisfy the criteria for consideration as a collaborative agreement, and is accounted for accordingly, in accordance with GAAP. Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market instruments. The Company places its cash and cash equivalents with high-quality, U.S. financial institutions and, to date has not experienced losses on any of its balances. Restricted Cash As of December 31, 2019, and March 31, 2019, the Company had $403,575 and $398,125 of restricted cash, respectively, related to debt service reserve in regard to the New Jersey Economic Development Authority ("NJEDA") bonds (see Note 5). Accounts Receivable Accounts receivable are comprised of balances due from customers, net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances. Inventory Inventory is recorded at the lower of cost or market on specific identification by lot number basis. Long-Lived Assets The Company periodically evaluates the fair value of long-lived assets, which include property and equipment and intangibles, whenever events or changes in circumstances indicate that its carrying amounts may not be recoverable. Property and equipment are stated at cost. Depreciation is provided on the straight-line method based on the estimated useful lives of the respective assets which range from three to forty years. Major repairs or improvements are capitalized. Minor replacements and maintenance and repairs which do not improve or extend asset lives are expensed currently. Upon retirement or other disposition of assets, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is recognized in income. Intangible Assets The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. Costs to acquire indefinite lived intangible assets, such as costs related to ANDAs are capitalized accordingly. The Company tests its intangible assets for impairment at least annually (as of March 31st) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company's expected future cash flows; a sustained, significant decline in the Company's stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company's segments; unanticipated competition; and slower growth rates. As of December 31, 2019, the Company did not identify any indicators of impairment. Please also see Note 4 for further details on intangible assets. Research and Development Research and development expenditures are charged to expense as incurred. Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company's condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future. Warrants and Preferred Shares The accounting treatment of warrants and preferred share series issued is determined pursuant to the guidance provided by ASC 470, Debt Distinguishing Liabilities from Equity Derivatives and Hedging Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation In accordance with the Company's Director compensation policy and certain employment contracts, director's fees and a portion of employee's salaries are to be paid via the issuance of shares of the Company's common stock, in lieu of cash, with the valuation of such share being calculated on a quarterly basis and equal to the average closing price of the Company's common stock. Earnings (Loss) Per Share Attributable to Common Shareholders' The Company follows ASC 260, Earnings Per Share The following is the computation of earnings (loss) per share applicable to common shareholders for the periods indicated: For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 Numerator Net loss attributable to common shareholders – basic $ (1,860,680 ) $ (2,344,318 ) $ (3,176,719 ) $ (6,615,616 ) Effect of dilutive instrument on net loss - (380,976 ) - (807,347 ) Net loss attributable to common shareholders - diluted $ (1,860,680 ) $ (2,725,924 ) $ (3,176,719 ) $ (7,422,963 ) Denominator Weighted average shares of common stock outstanding - basic 829,394,203 819,412,807 828,446,951 811,603,678 Dilutive effect of stock options, warrants and convertible securities - 56,074 - 56,074 Weighted average shares of common stock outstanding – diluted 829,394,203 819,468,881 828,466,951 811,659,752 Net loss per share attributable to common shareholders Basic $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.01 ) Diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.01 ) Fair Value of Financial Instruments ASC 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described as follows: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are unobservable for the asset or liability. Measured on a Recurring Basis The following table presents information about our liabilities measured at fair value on a recurring basis, aggregated by the level in the fair value hierarchy within which those measurements fell: Fair Value Measurement Using Amount at Fair Value Level 1 Level 2 Level 3 December 31 2019 Liabilities Derivative financial instruments – warrants $ 5,078,525 $ - $ - $ 5,078,525 March 31, 2019 Liabilities Derivative financial instruments – warrants $ 2,487,830 $ - $ - $ 2,487,830 See Note 11, for specific inputs used in determining fair value. The carrying amounts of the Company's financial assets and liabilities, such as cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate their fair values because of the short maturity of these instruments. Based upon current borrowing rates with similar maturities the carrying value of long-term debt approximates fair value. Non-Financial Assets that are Measured at Fair Value on a Non-Recurring Basis Non-financial assets such as intangible assets, and property and equipment are measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets in the periods presented. Treasury Stock The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of shareholders' deficit. Recently Adopted Accounting Pronouncements The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842) On April 1, 2019, the Company adopted Topic 842 using the modified retrospective basis with a cumulative-effect adjustment at the beginning of the period of adoption and therefore did not revise prior period information or disclosure. Further, the Company elected the package of practical expedients upon transition that allows the Company not to reassess the lease classification for expired and existing leases, whether initial direct costs qualify for capitalization for any expired or existing leases or whether any expired contracts are or contain leases. The adoption of ASU 2016-02 resulted in the recognition of operating leases and lease liabilities of approximately $0.6 million on the condensed consolidated balance sheet as of April 1, 2019. The operating leases and lease liabilities relate to a real estate lease. The impact of the adoption of Topic 842 on the accompanying condensed consolidated balance sheet as of April 1, 2019 was as follows: March 31, Adoption Adjustment April 1, Operating lease - right of use $ - $ 554,088 $ 554,088 Deferred rent liability $ 13,022 $ (13,022 ) $ - Lease obligation - operating lease $ - $ 191,817 $ 191,817 Lease obligation - operating lease, net of current portion $ - $ 375,293 $ 375,293 See additional lease disclosures in Note 9. Recently Issued Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments - Credit Losses Financial Instruments - Credit Losses (Topic 326), Targeted Transition Relief Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842). Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our condensed consolidated financial statements and related disclosures.

Inventory

Inventory	9 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2. INVENTORY Inventory consisted of the following: December 31, March 31, Finished goods $ 55,521 $ 575,699 Work-in-progress 238,052 189,069 Raw materials 3,516,828 3,750,955 3,810,401 4,515,723 Less: Inventory reserve - - $ 3,810,401 $ 4,515,723

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 3. PROPERTY AND EQUIPMENT, NET Property and equipment consisted of the following: December 31, March 31, Land, building and improvements $ 5,260,523 $ 5,260,523 Laboratory, manufacturing, warehouse and transportation equipment 12,135,950 12,078,340 Office equipment and software 373,601 373,601 Furniture and fixtures 383,103 383,103 18,153,177 18,095,567 Less: Accumulated depreciation (10,634,174 ) (9,651,718 ) $ 7,519,003 $ 8,443,849 Depreciation expense was $326,908 and $317,618 for the three months, and $982,456 and $931,180 for the nine months, ended December 31, 2019 and 2018, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4. INTANGIBLE ASSETS The following table summarizes the Company's intangible assets: December 31 2019 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 465,684 $ - $ - $ - $ 465,684 ANDA acquisition costs Indefinite 6,168,351 - - - 6,168,351 $ 6,634,035 $ - $ - $ - $ 6,634,035 March 31, 2019 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 465,684 $ - $ - $ - $ 465,684 ANDA acquisition costs Indefinite 7,247,317 - (1,078,966 ) - 6,168,351 $ 7,713,001 $ - $ (1,078,966 ) $ - $ 6,634,035 Patent application costs were incurred in relation to the Company's abuse deterrent opioid technology. Amortization of the patent costs will begin upon the issuance of marketing authorization by the FDA. Amortization will then be calculated on a straight-line basis through the expiry of the related patent(s).

NJEDA Bonds

NJEDA Bonds	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
NJEDA BONDS	NOTE 5. NJEDA BONDS During August 2005, the Company refinanced a bond issue occurring in 1999 through the issuance of Series A and B Notes tax-exempt bonds (the "NJEDA Bonds" and/or "Bonds"). During July 2014, the Company retired all outstanding Series B Notes, at par, along with all accrued interest due and owed. In relation to the Series A Notes, the Company is required to maintain a debt service reserve. The debt serve reserve is classified as restricted cash on the accompanying unaudited condensed consolidated balance sheets. The NJEDA Bonds require the Company to make an annual principal payment on September 1 st st st The following tables summarize the Company's bonds payable liability: December 31, March 31, Gross bonds payable NJEDA Bonds - Series A Notes $ 1,575,000 $ 1,670,000 Less: Current portion of bonds payable (prior to deduction of bond offering costs) (105,000 ) (95,000 ) Long-term portion of bonds payable (prior to deduction of bond offering costs) $ 1,470,000 $ 1,575,000 Bond offering costs $ 354,454 $ 354,453 Less: Accumulated amortization (203,221 ) (192,591 ) Bond offering costs, net $ 151,233 $ 161,862 Current portion of bonds payable - net of bond offering costs Current portions of bonds payable $ 105,000 $ 95,000 Less: Bonds offering costs to be amortized in the next 12 months (14,178 ) (14,178 ) Current portion of bonds payable, net of bond offering costs $ 90,822 $ 80,822 Long term portion of bonds payable - net of bond offering costs Long term portion of bonds payable $ 1,470,000 $ 1,575,000 Less: Bond offering costs to be amortized subsequent to the next 12 months (137,055 ) (147,685 ) Long term portion of bonds payable, net of bond offering costs $ 1,332,945 $ 1,427,315 Amortization expense was $3,545 and $3,544 for the three months, and $10,630 and $10,636 for the nine months, ended December 31, 2019 and 2018, respectively.

Loans Payable

Loans Payable	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
LOANS PAYABLE	NOTE 6. LOANS PAYABLE Loans payable consisted of the following: December 31, March 31, Equipment and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between March 2019 and July 2024 $ 886,817 $ 1,272,298 Less: Current portion of loans payable (356,137 ) (573,029 ) Long-term portion of loans payable $ 530,480 $ 699,269 The interest expense associated with the loans payable was $18,291 and $28,025 for the three months, and $63,170 and $86,765 for the nine months, ended December 31, 2019 and 2018, respectively.

Related Party Secured Promissor

Related Party Secured Promissory Note with Mikah Pharma LLC	9 Months Ended
	Dec. 31, 2019
Epic Pharma Llc [Member]
RELATED PARTY SECURED PROMISSORY NOTE WITH MIKAH PHARMA LLC	NOTE 7. RELATED PARTY SECURED PROMISSORY NOTE WITH MIKAH PHARMA LLC For consideration of the assets acquired on May 15, 2017, the Company issued a Secured Promissory Note (the "Note") to Mikah for the principal sum of $1,200,000. The Note matures on December 31, 2020 in which the Company shall pay the outstanding principal balance of the Note. Interest shall be computed on the unpaid principal amount at the per annum rate of ten percent (10%); provided, upon the occurrence of an Event of Default as defined within the Note, the principal balance shall bear interest from the date of such occurrence until the date of actual payment at the per annum rate of fifteen percent (15%). All interest payable hereunder shall be computed on the basis of actual days elapsed and a year of 360 days. Installment payments of interest on the outstanding principal shall be paid as follows: quarterly commencing August 1, 2017 and on November 1, February 1, May 1 and August 1 of each year thereafter. No principal or interest payments have been made on the Note since its issuance. All unpaid principal and accrued but unpaid interest shall be due and payable in full on the Maturity Date. The interest expense associated with the Note was $30,000 for the three months and $90,000 for the nine months ended December 31, 2019 and 2018, respectively. Accrued interest due and owing on this note was $315,000 and $225,000 as of December 31, 2019 and March 31, 2019, respectively.

Deferred Revenue

Deferred Revenue	9 Months Ended
	Dec. 31, 2019
Deferred Revenue Disclosure [Abstract]
DEFERRED REVENUE	NOTE 8. DEFERRED REVENUE Deferred revenues in the aggregate amount of $492,224 as of December 31, 2019, were comprised of a current component of $430,000 and a long-term component of $62,224. Deferred revenues in the aggregate amount of $1,252,223 as of March 31, 2019, were comprised of a current component of $1,013,333 and a long-term component of $238,890. These line items represent the unamortized amounts of a $200,000 advance payment received for a TAGI licensing agreement with a fifteen-year term beginning in September 2010 and ending in August 2025 and the $5,000,000 advance payment Epic Collaborative Agreement with a five-year term beginning in June 2015 and ending in May 2020. These advance payments were recorded as deferred revenue when received and are earned, on a straight-line basis over the life of the licenses. The current component is equal to the amount of revenue to be earned during the 12-month period immediately subsequent to the balance date and the long-term component is equal to the amount of revenue to be earned thereafter.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9. COMMITMENTS AND CONTINGENCIES Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company's condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. Operating Leases – 135 Ludlow Ave. The Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the "135 Ludlow Ave. lease"). The 135 Ludlow Ave. lease is for approximately 15,000 square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire 35,000 square feet of floor space in the building ("135 Ludlow Ave. modified lease"). The 135 Ludlow Ave. modified lease includes an initial term, which expired on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021. The 135 Ludlow Ave. property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company's manufacturing resources are in progress. The Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company has elected to account for non-lease components associated with our leases and lease components as a single lease component. The Company recognizes a right-of use asset, which represents the Company's right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company's obligation to make payments arising over the lease term. The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing rate. Lease assets and liabilities are classified as follows on the condensed consolidated balance sheet at December 31, 2019: Lease Classification As of Assets Operating Operating lease – right to use asset $ 412,063 Total leased assets $ 412,063 Liabilities Current Operating Lease obligation – operating lease $ 203,984 Long-term Operating Lease obligation – operating lease, net of current portion 221,166 Total lease liabilities $ 425,150 Rent expense is recorded on the straight-line basis. Rent expense under the 135 Ludlow Ave. modified lease for the three months ended December 31, 2019 and 2018 was $18,296 and $54,909, and $128,072 and $164,757 for the nine months ended December 31, 2019 and 2018, respectively. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations. The table below show the future minimum rental payments, exclusive of taxes, insurance and other costs, under the 135 Ludlow Ave. modified lease: Years ending March 31, Amount 2020 — Remaining $ 55,986 2021 225,063 2022 171,315 Total future minimum lease payments 452,634 Less: interest (27,214 ) Present value of lease payments $ 425,150 The weighted-average remaining lease term and the weighted-average discount rate of our lease was as follows: Lease Term and Discount Rate December 31, Remaining lease term (years) Operating leases 2.0 Discount rate Operating leases 6 % The Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, Asset Retirement and Environmental Obligations – Asset Retirement Obligations

Preferred Stock

Preferred Stock	9 Months Ended
	Dec. 31, 2019
Equity [Abstract]
PREFERRED STOCK	NOTE 10. PREFERRED STOCK Series J convertible preferred stock On April 28, 2017, the Company created the Series J Convertible Preferred Stock ("Series J Preferred") in conjunction with the Certificate of Designations ("Series J COD"). A total of 50 shares of Series J Preferred were authorized, 24.0344 shares are issued and outstanding, with a stated value of $1,000,000 per share and a par value of $0.01 as of December 31, 2019. The shares were issued pursuant to an Exchange Agreement with Nasrat Hakim, ("Hakim") a related party and the Company's President, CEO and Chairman of the Board of Directors. Pursuant to the Exchange Agreement the Company exchanged 158,017,321 shares of Common Stock for 24.0344 shares of Series J Preferred and warrants to purchase 79,008,661 shares of common stock at $0.1521 per share. The aggregate stated value of the Series J Preferred issued was equal to the aggregate value of the shares of common stock exchanged, with such value of each share of Common Stock exchanged being equal to the closing price of the Common Stock on April 27, 2017. In connection with the Exchange Agreement, the Company also issued warrants to purchase 79,008,661 shares of common stock at $0.1521 per share, and such warrants were classified as liabilities on the accompanying unaudited condensed consolidated balance sheet as of December 31, 2019 (See Note 11). Each Series J Preferred is convertible at the option of the holder into shares of common stock, that is the earlier of (i) the date that shareholder approval is obtained, and the requisite corporate action has been effected regarding a Fundamental Transaction (as defined in the Series J COD); or (ii) not less than three years subsequent to the Original Issue Date (the date of the first issuance of any shares of the Series J Preferred Stock) (the "Conversion Date"). The number of common shares is calculated by dividing the Stated Value of such share of Series J Preferred by the Conversion Price. The conversion price for the Series J Preferred shall equal $0.1521, subject to adjustment as discussed below. Based on the current conversion price, the Series J Preferred is convertible into 158,017,321 shares of common stock. The conversion price is subject to the following adjustments: (i) stock dividends and splits, (ii) sale or grant of shares below the conversion price, (iii) pro rata distributions; or (iv) fundamental changes (merger, consolidation, or sale of all or substantially all assets). If upon any Conversion Date there is not a sufficient number of authorized shares of Common Stock (that are not issued, outstanding or reserved for issuance) available to effect the entire conversion of the then outstanding shares of Series J Preferred Stock and the then outstanding common stock purchase warrants issued in conjunction therewith (an "Authorized Share Deficiency"), such conversion shall not exceed the Issuable Maximum (as defined in the Series J COD); however, the Company shall use its best efforts to obtain shareholder approval within two (2) years of the date of first issuance of Series J Preferred Stock to permit the balance of the conversion. If shareholder approval is not obtained due to an insufficient number of shareholder votes for passage, the Company shall continue to solicit for shareholder approval annually thereafter. As of March 31, 2019, the Company does not have a sufficient number of unreserved authorized shares to effect the entire conversion, notwithstanding that the earliest possible Conversion Date is April 28, 2020. Solely during any period of time during which an Authorized Share Deficiency exists commencing on or after the fourth anniversary of the Original Issue Date ("Dividend Commencement Date" and collectively the "Dividend Entitlement Period"), holders of Series J Preferred shall be entitled to receive, and the Company shall pay, dividends at the rate per share (as a percentage of the Stated Value per share) of 20% per annum, payable quarterly, in arrears, on January 1, April 1, July 1 and October 1, in cash or duly authorized, validly issued, fully paid and non-assessable shares of Series J Preferred, or a combination thereof (the amount to be paid in shares of Series J Preferred, the "Dividend Share Amount"). The form of dividend payments to each holder shall be made, at the option of the Holders, (i) in cash, to the extent that funds are legally available for the payment of dividends in cash, (ii) in shares of Series J Preferred Stock, or (iii) a combination thereof. The Series J Preferred shall rank senior to the common stock with respect to payment of dividends and pari passu to the common stock with respect to liquidation, dissolution or winding up of the Company. The holders of the Series J Preferred shall have voting rights on any matter presented to the shareholders of the Company for their action or consideration at any meeting of shareholders of the Company (or by written consent of shareholders in lieu of meeting). Each holder shall be entitled to cast the number of votes equal to the number of whole shares of common stock into which the shares of Series J Preferred held by the holder are convertible as of the record date for determining the shareholders entitled to vote on such matter regardless of whether an Authorized Share Deficiency Exists. The Company has determined that the Series J Preferred host instrument was more akin to equity than debt and that the above identified conversion feature, subject to adjustments, was clearly and closely related to the host instrument, and accordingly bifurcation and classification of the conversion feature as a derivative liability was not required. The Company has accounted for the Series J Preferred as contingently redeemable preferred stock for which redemption is not probable. Accordingly, the Series J Preferred is presented in mezzanine equity based on their initial measurement amount (fair value), as required by ASC 480-10-S99, Distinguishing Liabilities from Equity – SEC Materials. No subsequent adjustment of the initial measurement amounts for these contingently redeemable Series J Preferred is necessary unless the redemption of the Series J Preferred becomes probable. Accordingly, the amount presented as temporary equity for the contingently redeemable Series J Preferred outstanding is its issuance-date fair value. The Series J Preferred was initially measured at its fair value, $13,903,960 at April 28, 2017. The fair value of the Series J Preferred issued by the Company pursuant to the exchange agreement was calculated using a Monte Carlo Simulation because of the probability assumptions associated with the shareholder approval provisions; the following are the Monte Carlo inputs: April 28, 2017 Fair value of the Company's common stock $ 0.1521 Initial exercise price $ 0.1521 Number of Series J Preferred issued 24.0344 Fully diluted shares outstanding as of measurement date 923,392,780 Risk-free rate 2.30 % Volatility 90.00 % Shareholder approval threshold $ 0.1521 Probability of approval is ending stock price is greater than threshold - midpoint 82.50 % Probability of approval is ending stock price is greater than threshold - midpoint 17.50 % Trials 200,000 Authorized, issued and outstanding shares, along with carrying value as of March 31, 2019 are as follows: Shares authorized 50 Shares outstanding 24.0344 Par value $ 0.01 Stated value $ 1,000,000 Conversion price $ 0.1521 Common shares to be issued upon redemption 158,017,321 Carrying value of Series J convertible preferred stock $ 13,903,960 Increase in Authorized Shares An amendment to the Company's Articles of Incorporation to increase the number of shares of common stock the Company is authorized to issue from 995,000,000 shares to 1,445,000,000 shares was approved at the Company's Annual Meeting of Shareholders held on December 4, 2019. Prior to the approval of the increase in the number of authorized shares, there were insufficient authorized shares if the Series J Preferred Stock were converted. As a result, the shares were classified in mezzanine equity. After the approval of the increase in the number of authorized shares, there are now sufficient authorized shares if the Series J Preferred Stock were converted. With the approval of the increase in the number of authorized shares, there is no longer the presumption that a cash settlement will be required. Therefore, the Series J Preferred has been reclassified from mezzanine equity to permanent equity at its current carrying amount of $13,903,960 on the accompanying condensed consolidated balance sheet.

Derivative Financial Instrument

Derivative Financial Instruments - Warrants	9 Months Ended
	Dec. 31, 2019
Derivative Financial Instruments Warrants Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS - WARRANTS	NOTE 11. DERIVATIVE FINANCIAL INSTRUMENTS – WARRANTS The Company evaluates and accounts for its freestanding instruments in accordance with ASC 815, Accounting for Derivative Instruments and Hedging Activities The Company issued warrants, with a term of seven years, to Nasrat Hakim, pursuant to the Exchange Agreement detailed below. A summary of warrant activity is as follows: December 31 2019 March 31, 2019 Warrant Shares Weighted Avg. Exercise Price Warrant Shares Weighted Avg. Exercise Price Balance at beginning of period 79,008,661 $ 0.1521 79,008,661 $ 0.1521 Warrants granted pursuant to the issuance of Series J convertible preferred shares - - - - Warrants exercised, forfeited and/or expired, net - - - - Balance at end of period 79,008,661 $ 0.1521 79,008,661 $ 0.1521 On April 28, 2017, the Company entered into an exchange agreement (the "Exchange Agreement" "Series J Preferred Securities" The Series J Warrants are exercisable for a period of 10 years from the date of issuance, commencing on the earlier of (i) the date that Shareholder Approval is obtained, and the requisite corporate action has been effected; or (ii) April 28, 2020. The initial exercise price is $0.1521 per share and the Series J Warrants can be exercised for cash or on a cashless basis. The exercise price is subject to adjustment for any issuances or deemed issuances of common stock or common stock equivalents at an effective price below the then exercise price. Such exercise price adjustment feature prohibits the Company from being able to conclude the warrants are indexed to its own stock and thus such warrants are classified as liabilities and measured initially and subsequently at fair value. The Series J Warrants also provide for other standard adjustments upon the happening of certain customary events. The Series J Warrants are not exercisable during any period when an Authorized Share Deficiency exists and will expire on the expiry date, without regards to the existence of an Authorized Shares Deficiency (see Note 10). As of March 31, 2019, the Company does not have a sufficient number of unreserved authorized shares to effect the entire conversion of the Series J Preferred, therefore the Series J Warrants are not currently exercisable. Please also see Note 10. The fair value of the warrants issued by the Company pursuant to the issuance of Series J convertible preferred shares (79,008,661 warrant shares) was calculated using a Monte Carlo Simulation because of the probability assumptions associated with the Shareholder Approval provisions. The following are the key assumptions used in the Monte Carlo Simulation: March 31, Fair value of the Company's common stock $ 0.9900 Initial exercise price $ 0.1521 Number of common warrants 79,008,661 Fully diluted shares outstanding as of measurement date 824,946,559 Warrant term (in years) 8.08 Risk-free rate 2.35 % Volatility 90.00 % Shareholder approval threshold $ 0.1580 Probability of approval is ending stock price is greater than threshold - midpoint 82.50 % Probability of approval is ending stock price is greater than threshold - midpoint 17.50 % Trials 100,000 Fair value of derivative financial instruments - warrants $ 2,487,830 The fair value of the warrants issued by the Company pursuant to the issuance of Series J convertible preferred shares (79,008,661 warrant shares) was calculated using a Black-Scholes model instead of a Monte Simulation because the probability with the shareholder approval provisions was no longer a factor. The following assumptions were used in the Black-Scholes model to calculate the fair value of warrants issued by the Company pursuant to the issuance of Series J convertible preferred shares (79,008,661 warrant shares): December 31, Fair value of the Company's common stock $ 0.0925 Volatility 83.89 % Initial exercise price $ 0.1521 Warrant term (in years) 7.3 Risk free rate 1.83 % The changes in warrants (Level 3 financial instruments) measured at fair value on a recurring basis for the nine months ended December 31, 2019 were as follows: Outstanding at March 31, 2019 $ 2,487,830 Change in fair value of derivative financial instruments - warrants 2,590,695 Balance at December 31, 2019 $ 5,078,525

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
SHAREHOLDERS' EQUITY	NOTE 12. SHAREHOLDERS' EQUITY Lincoln Park Capital – April 10, 2014 Purchase Agreement In April 2014, the Company entered into a Purchase Agreement (the " Lincoln Park Purchase Agreement Purchase Agreement Registration Rights Agreement Lincoln Park Upon execution of the Purchase Agreement, the Company issued 1,928,641 shares of common stock to Lincoln Park pursuant to the Purchase Agreement as consideration for its commitment to purchase additional shares of common stock under that agreement and the Company was obligated to issue up to an additional 1,928,641 commitment shares to Lincoln Park pro rata as up to $40.0 million of common stock purchased by Lincoln Park. The Purchase Agreement expired on June 1, 2017. During the term of the Purchase Agreement, the Company sold an aggregate of 110.6 million shares to Lincoln Park, for aggregate gross proceeds of approximately $27.0 million. In addition, the Company issued an aggregate of 3.2 million commitment shares. Lincoln Park Capital – May 1, 2017 Purchase Agreement On May 1, 2017, the Company entered into a purchase agreement (the " 2017 LPC Purchase Agreement 2017 LPC Registration Rights Agreement Under the terms and subject to the conditions of the 2017 LPC Purchase Agreement, the Company has the right to sell to and Lincoln Park is obligated to purchase up to $40 million in shares of common stock, subject to certain limitations, from time to time, over the 36-month period commencing on June 5, 2017. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 500,000 shares of common stock on any business day, provided that at least one business day has passed since the most recent purchase, increasing to up to 1,000,000 shares, depending upon the closing sale price of the common stock (such purchases, " Regular Purchases In connection with the 2017 LPC Purchase Agreement, the Company issued to Lincoln Park 5,540,551 shares of common stock and is required to issue up to 5,540,551 additional shares of Common Stock pro rata as the Company requires Lincoln Park to purchase shares under the 2017 LPC Purchase Agreement over the term of the agreement. Lincoln Park has represented to the Company, among other things, that it is an "accredited investor" (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the "Securities Act")). The Company sold the securities in reliance upon an exemption from registration contained in Section 4(a)(2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The 2017 LPC Purchase Agreement and the 2017 LPC Registration Rights Agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the 2017 LPC Purchase Agreement at any time, at no cost or penalty. Actual sales of shares of common stock to Lincoln Park under the 2017 LPC Purchase Agreement will depend on a variety of factors to be determined by us from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the appropriate sources of funding for us and our operations. There are no trading volume requirements or, other than the limitation on beneficial ownership discussed above, restrictions under the 2017 LPC Purchase Agreement. Lincoln Park has no right to require any sales by the Company but is obligated to make purchases from the Company as directed in accordance with the 2017 LPC Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares. The net proceeds received by the Company under the 2017 LPC Purchase Agreement will depend on the frequency and prices at which the Company sells shares of common stock to Lincoln Park. A registration statement on Form S-3 During the nine months ended December 31, 2019, a total of 8,895,233 shares were sold to Lincoln Park pursuant to the 2017 LPC Agreement for net proceeds totaling $806,987. In addition, 111,778 shares were issued to Lincoln Park as additional commitment shares, pursuant to the 2017 LPC Agreement. During the nine months ended December 31, 2018, a total of 17,642,083 shares were sold to Lincoln Park pursuant to the 2017 LPC Agreement for net proceeds totaling $1,669,829. In addition, 231,295 shares were issued to Lincoln Park as additional commitment shares, pursuant to the 2017 LPC Agreement.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 13. STOCK-BASED COMPENSATION Part of the compensation paid by the Company to its Directors and employees consists of the issuance of common stock or via the granting of options to purchase common stock. Stock-based Director Compensation The Company's Director compensation policy was instituted in October 2009 and further revised in January 2016, includes provisions that a portion of director's fees are to be paid via the issuance of shares of the Company's common stock, in lieu of cash, with the valuation of such shares being calculated on quarterly basis and equal to the average closing price of the Company's common stock. During the nine months ended December 31, 2019, the Company did not issue any shares of common stock to its Directors in payment of director's fees. During the nine months ended December 31, 2019, the Company accrued director's fees totaling 67,500, which will be paid via cash payments totaling $22,500 and the issuance of 585,417 shares of Common Stock. As of December 31, 2019, the Company owed its Directors a total of $60,000 in cash payments and 1,379,033 shares of Common Stock in payment of director fees totaling $180,000 due and owing. The Company anticipates that these shares of Common Stock will be issued prior to the end of the current fiscal year. Stock-based Employee/Consultant Compensation Employment contracts with the Company's President and Chief Executive Officer, Chief Financial Officer and certain other employees and engagement contracts with certain consultants include provisions for a portion of each employee's salaries or consultant's fees to be paid via the issuance of shares of the Company's Common Stock, in lieu of cash, with the valuation of such shares being calculated on a quarterly basis and equal to the average closing price of the Company's Common Stock. During the nine months ended December 31, 2019, the Company did not issue any shares pursuant to employment contracts with the Company's President and Chief Executive Officer, Chief Financial Officer or certain other employees. During the nine months ended December 31, 2019, the Company did not issue any shares pursuant to the engagement contracts with certain consultants. As of December 31, 2019, the Company accrued salaries totaling $603,750 owed to the Company's President and Chief Executive Officer, Chief Financial Officer and certain other employees which will be paid via the issuance of 7,854,334 shares of Common Stock. As of December 31, 2019, the Company owed its President and Chief Executive Officer, Chief Financial Officer and certain other employees' salaries totaling $2,110,000 which will be paid via the issuance of 22,536,856 shares of Common Stock. Options Under its 2014 Stock Option Plan and prior options plans, the Company may grant stock options to officers, selected employees, as well as members of the Board of Directors and advisory board members. All options have generally been granted at a price equal to or greater than the fair market value of the Company's Common Stock at the date of the grant. Generally, options are granted with a vesting period of up to three years and expire ten years from the date of grant. Weighted Average Shares Weighted Remaining Contractual Aggregate Underlying Options Exercise Term (in years) Intrinsic Outstanding at April 1, 2019 6,158,000 $ 0.15 5.0 $ 87,330 Forfeited and expired (283,000 ) $ 0.15 7.8 $ - Outstanding at December 31, 2019 5,875,000 $ 0.14 4.0 $ - Exercisable at December 31 2019 5,541,668 $ 0.14 4.0 $ 67,500 The aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company common stock as of December 31, 2019 and March 31, 2019 of $0.0925 and $0.10, respectively.

Concentrations and Credit Risk

Concentrations and Credit Risk	9 Months Ended
	Dec. 31, 2019
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND CREDIT RISK	NOTE 14. CONCENTRATIONS AND CREDIT RISK Revenues Three customers accounted for approximately 94% of the Company's revenues for the nine months ended December 31, 2019. These three customers accounted for approximately 57%, 24%, and 13% of revenues each. The same three customers accounted for approximately 69%, 12%, and 13% of revenues each, respectively, for the three months ended December 31, 2019. Three customers accounted for substantially all the Company's revenues for the nine months ended December 31, 2018. These three customers accounted for approximately 63%, 17%, and 16% of revenues each, respectively. The same three customers accounted for approximately 58%, 21%, and 7% of revenues each, respectively, for the three months ended December 31, 2018. Accounts Receivable Three customers accounted for approximately 90% the Company's accounts receivable as of December 31, 2019. These three customers accounted for approximately 60%, 22% and 8% of accounts receivable each. Four customers accounted for substantially all the Company's accounts receivable as of March 31, 2019. These four customers accounted for approximately 38%, 34%, 19%, and 4% of accounts receivable each. Purchasing Eight suppliers accounted for more than 85% of the Company's purchases of raw materials for the nine months ended December 31, 2019. Included in these eight suppliers were three suppliers that accounted for approximately 34%, 25%, and 11% of purchases each. Seven suppliers accounted for more than 75% of the Company's purchases of raw materials for the nine months ended December 31, 2018. Included in these seven suppliers are two suppliers that accounted for approximately 40%, 16%, and 15% of purchases each.

Segment Results

Segment Results	9 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
SEGMENT RESULTS	NOTE 15. SEGMENT RESULTS ASC 280-10-50 requires use of the "management approach" model for segment reporting. The management approach is based on the way a company's management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. The Company has determined that its reportable segments are ANDAs for generic products and NDAs for branded products. The Company identified its reporting segments based on the marketing authorization relating to each and the financial information used by its chief operating decision maker to make decisions regarding the allocation of resources to and the financial performance of the reporting segments. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company's unaudited condensed consolidated financial statements. The following represents selected information for the Company's reportable segments: For the Three Months Ended For the Nine Months Ended December 31, 2019 2018 2019 2018 Operating Income (Loss) by Segment ANDA $ 2,431,906 $ (582,822 ) $ 2,538,560 $ (1,129,324 ) NDA 135,500 (744,393 ) 407,245 (1,250,420 ) $ 2,567,406 $ (1,327,215 ) $ 2,945,805 $ (2,379,744 ) The table below reconciles the Company's operating loss by segment to loss from operations before provision for income taxes as reported in the Company's unaudited condensed consolidated statements of operations. For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 Operating income (loss) by segment $ 2,567,406 $ (1,327,215 ) $ 2,945,805 $ (2,379,744 ) Corporate unallocated costs (739,790 ) (667,002 ) (1,740,579 ) (3,111,346 ) Interest income 2,334 1,733 10,667 4,570 Interest expense (94,515 ) (89,897 ) (283,649 ) (279,037 ) Depreciation and amortization expense (323,368 ) (321,164 ) (986,001 ) (891,390 ) Non-cash items (213,052 ) (321,749 ) (532,267 ) (766,016 ) Change in fair value of derivative instruments – warrants (3,059,695 ) 380,976 (2,590,695 ) 807,347 Loss from operations $ (1,860,680 ) $ (2,344,318 ) $ (3,176,719 ) $ (6,615,616 )

Collaborative Agreement with Ep

Collaborative Agreement with Epic Pharma LLC	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
COLLABORATIVE AGREEMENT WITH EPIC PHARMA LLC	NOTE 16. COLLABORATIVE AGREEMENT WITH EPIC PHARMA LLC On June 4, 2015, the Company entered into the 2015 Epic License Agreement, which provides for the exclusive right to market, sell and distribute, by Epic Pharma LLC ("Epic") of SequestOx™, an abuse deterrent opioid which employs the Company's proprietary pharmacological abuse-deterrent technology. Epic will be responsible for payment of product development and pharmacovigilance costs, sales, and marketing of SequestOx™, and Elite will be responsible for the manufacture of the product. Under the 2015 Epic License Agreement, Epic will pay Elite non-refundable payments totaling $15 million, with such amount representing the cost of an exclusive license to ELI-200, the cost of developing the product and certain filings and a royalty based on an amount equal to 50% of profits derived from net product sales as defined in the 2015 Epic License Agreement. The initial term of the exclusive right to product development sales and distribution is five years ("Epic Exclusivity Period"); the license is renewable upon mutual agreement at the end of the initial term. In June 2015, Elite received non-refundable payments totaling $5.0 million from Epic for the exclusive right to product development sales and distribution of SequestOx™ pursuant to the Epic Collaborative Agreement, under which it agreed to not permit marketing or selling of SequestOx™ within the United States of America to any other party. Such exclusive rights are considered a significant deliverable element of the Epic Collaborative Agreement pursuant to ASC 605-25, Revenue Recognition – Multiple Element Arrangements In addition, in January 2016, a New Drug Application for SequestOx™ was filed, thereby earning the Company a non-refundable $2.5 million milestone, pursuant to the 2015 Epic License Agreement. The filing of this NDA represents a significant deliverable element as defined within the Epic Collaborative pursuant to ASC 605-25, Revenue Recognition – Multiple Element Arrangements To date, the Company received payments totaling $7.5 million pursuant to the 2015 Epic License Agreement, with all amounts being non-refundable. An additional $7.5 million is due upon approval by the FDA of the NDA filed for SequestOx™, and license fees based on commercial sales of SequestOx™. Revenues relating to these additional amounts due under the 2015 Epic License Agreement will be recognized as the defined elements are completed and collectability is reasonably assured. Please note that on July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx™ NDA is complete and the application is not ready for approval in its present form. On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for or SequestOx™. The mean Tmax (the amount of time that a drug is present at the maximum concentration in serum) of SequestOx™ was 4.6 hr. with a range of 0.5 hr. to 12 hr. and the mean Tmax of the comparator, Roxicodone®, was 3.4 hr. with a range of 0.5 hr. to 12 hr. A key objective for the study was to determine if the reformulated SequestOx™ had a similar Tmax to the comparator when taken with a high fat meal. Based on these results, the Company paused clinical trials for this formulation of SequestOx™. On January 30, 2018, the Company reported positive topline results from a pilot study conducted for a modified SequestOx™ wherein, based on the results of this pilot study, the modified SequestOx™ formulation is expected to achieve bioequivalence with a Tmax range equivalent to the reference product when conducted in a pivotal trial under fed conditions. The Company has provided the pilot data to the FDA, requesting clarification as to the requirements for resubmission of the NDA. The FDA has provided guidance for repeated bio-equivalence studies in order to bridge the new formulation to the original SequestOx™ studies and also extended our filing fee waiver until July 2020. Due to the prohibitive cost of such repeated bio-equivalence studies, the Company has paused development of this product. The 2015 Epic License Agreement expires on June 4, 2020, and Epic has previously advised the Company of their desire to extend this agreement. While discussions are ongoing, they are directly correlated to the regulatory status of SequestOx™. Furthermore, there can be no assurances that the parties will reach mutual agreement to extend the term of this agreement and no assurances that the terms and conditions of the agreement will be similar in all material aspects in the event that the agreement is extended by mutual consent of the parties. Non-receipt by the Company of the remaining $7.5 million milestone will have a material adverse effect on the Company's financial condition.

Collaborative Agreement with Su

Collaborative Agreement with Sungen Pharma LLC	9 Months Ended
	Dec. 31, 2019
Collaborative Agreement with Sungen Pharma LLC [Abstract]
COLLABORATIVE AGREEMENT WITH SUNGEN PHARMA LLC	NOTE 17. COLLABORATIVE AGREEMENT WITH SUNGEN PHARMA LLC On August 24, 2016, the Company entered into the SunGen Agreement. The SunGen Agreement provides that Elite and SunGen Pharma LLC will engage in the research, development, sales, and marketing of four generic pharmaceutical products. Two of the products are classified as CNS stimulants (the "CNS Products") and two of the products are classified as beta blockers (the "Beta Blocker Products"). Under the terms of the SunGen Agreement, Elite and SunGen will share in the responsibilities and costs in the development of these products and will share in the profits from sales of the Products. Upon approval, the know-how and intellectual property rights to the products will be owned jointly by Elite and SunGen. SunGen shall have the exclusive right to market and sell the Beta Blocker Products using SunGen's label and Elite shall have the exclusive right to market and sell the CNS Products using Elite's label. Elite will manufacture and package all four products on a cost-plus basis. On December 1, 2016 and July 24, 2017, Elite Labs and SunGen executed an amendment to the parties' 2016 Development and License Agreement (the "Amended Agreement"), to undertake and engage in the research, development, sales and marketing of four additional generic pharmaceutical products bringing the total number of products under the amended agreement to eight. The product classes for the additional four products include antidepressants, antibiotics, and antispasmodics. Under the terms of the Amended Agreement, Elite and SunGen will share in the responsibilities and costs in the development of these products and will share substantially in the profits from sales of the products. Upon approval, the know-how and intellectual property rights to the products will be owned jointly by Elite and SunGen. Three products will be owned jointly by Elite and SunGen; three shall be owned by SunGen while Elite shall have the marketing rights once the products are approved by the FDA; and two shall be owned by Elite while SunGen shall have the marketing rights once the products are approved by the FDA. Elite will manufacture and package all eight products on a cost-plus basis. On December 10, 2018, the Company received approval from the FDA for an ANDA filed for a generic version of Adderall®, an immediate-release mixed salt of a single entity amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate), with strengths of 5mg, 7.5mg. 10mg, 12.5mg, 15mg, 20mg, and 30mg tablets. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. This approval represents the first FDA approval received for a product co-developed with SunGen under the SunGen Agreement. The first commercial shipment of this product occurred in April 2019. The product is currently marketed by Lannett Company Inc. ("Lannett") under license granted pursuant a strategic marketing alliance dated March 6, 2019 (the "Lannett Alliance"). On May 24, 2018, the Company filed an ANDA with the FDA for a generic version of an extended release CNS stimulant. The ANDA represents the second filing for a product co-developed with SunGen under the SunGen Agreement. This product will also be marketed by Lannett pursuant to the Lannett Alliance. On January 3, 2019, the Company filed an ANDA with the FDA for a generic version of an antibiotic product. The ANDA represents the third filing for a product co-developed with SunGen under the SunGen Agreement. There can be no assurances that any of these products, even those for which ANDAs have been filed, will receive marketing authorization and achieve commercialization within a reasonable time period, or at all. In addition, even if marketing authorization is received, including the product for which such marketing authorization has already been received, there can be no assurances that there will be future revenues of profits, or that any such future revenues or profits would be in amounts that provide adequate return on the significant investments made to secure these marketing authorizations.

Related Party Transaction Agree

Related Party Transaction Agreements With Epic Pharma LLC	9 Months Ended
	Dec. 31, 2019
Epic Pharma Llc [Member]
RELATED PARTY TRANSACTION AGREEMENTS WITH EPIC PHARMA LLC	NOTE 18. RELATED PARTY TRANSACTION AGREEMENTS WITH EPIC PHARMA LLC The Company has entered into two agreements with Epic which constitute agreements with a related party due to the management of Epic including a member on our Board of Directors at the time such agreements were executed. On June 4, 2015, the Company entered into the 2015 Epic License Agreement (please see Note 16 above). The 2015 Epic License Agreement includes milestone payments totaling $10 million upon the filing with and approval of an NDA with the FDA. The Company has determined these milestones to be substantive, with such assessment being made at the inception of the 2015 Epic License Agreement, and based on the following: ● The Company's performance is required to achieve each milestone; and ● The milestones will relate to past performance, when achieved; and ● The milestones are reasonable relative to all of the deliverables and payment terms within the 2015 Epic License Agreement After marketing authorization is received from the FDA, Elite will receive a license fee which is based on profits achieved from the commercial sales of ELI-200. On January 14, 2016, the Company filed an NDA with the FDA for SequestOx™, thereby earning a $2.5 million milestone pursuant to the 2015 Epic License Agreement. The Company has received payment of this amount from Epic. An additional $7.5 million is due upon approval by the FDA of the NDA filed for SequestOx™. Please note that on July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx™ NDA is complete and the application is not ready for approval in its present form. On December 21, 2016, the Company met with the FDA for an end-of-review meeting to discuss steps that it could take to obtain approval of SequestOx™. Based on this and the meeting minutes received from the FDA on January 23, 2017, the Company formulated a plan to address the issues cited by the FDA in the CRL, with such plan including, without limitation, modifying the SequestOx™ formulation, conducting bioequivalence and bioavailability fed and fasted studies, comparing the modified formulation to the original formulation. On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for SequestOx™. This study resulted in a mean Tmax of 4.6 hours, with a range of 0.5 hour to 12 hours and a mean Tmax of the comparator, Roxicodone ® On October 2, 2013, Elite executed the Epic Pharma Manufacturing and License Agreement (the "Epic Generic Agreement"). The Epic Generic Agreement, which expired on October 2, 2018 granted rights to Epic to manufacture twelve generic products whose ANDA's are owned by Elite, and to market, in the United States and Puerto Rico, six of these products on an exclusive basis, and the remaining six products on a non-exclusive basis. These products were to be manufactured at Epic, with Epic being responsible for the manufacturing site transfer supplements that are a prerequisite to each product being approved for commercial sale. In addition, Epic was to be responsible for all regulatory and pharmacovigilance matters, as well as all marketing and distribution activities. Elite has no further obligations or deliverables under the Epic Generic Agreement. Pursuant to the Epic Generic Agreement, Elite was to receive $1.8 million, payable in increments that require the commercialization of all six exclusive products if the full amount is to be received, plus license fees equal to a percentage that is not less than 50% and not greater than 60% of profits achieved from commercial sales of the products, as defined in the Epic Generic Agreement. The Epic Generic Agreement expired on October 2, 2018 with Epic launching four of the six exclusive products and Elite collecting $1.0 million of the total $1.8 million fee. The 2015 Epic License Agreement contains license fees that will be earned and payable to the Company, after the FDA has issued marketing authorization(s) for the related product(s). License fees are based on commercial sales of the products achieved by Epic and calculated as a percentage of net sales dollars realized from such commercial sales. Net sales dollars consist of gross invoiced sales less those costs and deductions directly attributable to each invoiced sale, including, without limitation, cost of goods sold, cash discounts, Medicaid rebates, state program rebates, price adjustments, returns, short date adjustments, charge backs, promotions, and marketing costs. The rate applied to the net sales dollars to determine license fees due to the Company is equal to an amount negotiated and agreed to by the parties to each agreement, with the following significant factors, inputs, assumptions, and methods, without limitation, being considered by either or both parties: ● Assessment of the opportunity for each product in the market, including consideration of the following, without limitation: market size, number of competitors, the current and estimated future regulatory, legislative, and social environment for abuse deterrent opioids and the other generic products to which the underlying contracts are relevant; ● Assessment of various avenues for monetizing SequestOx™ and the twelve ANDA's owned by the Company, including the various combinations of sites of manufacture and marketing options; ● Elite's resources and capabilities with regards to the concurrent development of abuse deterrent opioids and expansion of its generic business segment, including financial and operational resources required to achieve manufacturing site transfers for twelve approved ANDA's; ● Capabilities of each party with regards to various factors, including, one or more of the following: manufacturing, marketing, regulatory and financial resources, distribution capabilities, ownership structure, personnel, assessments of operational efficiencies and entity stability, company culture and image; ● Stage of development of SequestOx™ and manufacturing site transfer and regulatory requirements relating to the commercialization of the generic products at the time of the discussions/negotiations, and an assessment of the risks, probability, and time frames for achieving marketing authorizations from the FDA for each product. ● Assessment of consideration offered; and ● Comparison of the above factors among the various entities with whom the Company was engaged in discussions relating to the commercialization of SequestOx™ and the manufacture/marketing of the twelve generics related to the Epic Generic Agreement. This transaction is not to be considered as an arms-length transaction. Please also note that, effective April 7, 2016, all Directors on the Company's Board of Directors that were also owners/managers of Epic had resigned as Directors of the Company and all current members of the Company's Board of Directors have no relationship to Epic. Accordingly, Epic no longer qualifies as a party that is related to the Company.

Manufacturing, License and Deve

Manufacturing, License and Development Agreements	9 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
MANUFACTURING, LICENSE AND DEVELOPMENT AGREEMENTS	NOTE 19. MANUFACTURING, LICENSE AND DEVELOPMENT AGREEMENTS The Company has entered into the following active agreements: ● License agreement with Precision Dose, dated September 10, 2010 (the "Precision Dose License Agreement"); ● Development and License Agreement with SunGen (the "SunGen Agreement"); ● Strategic Marketing Alliance with Glenmark Pharmaceuticals, Inc. USA dated May 22, 2018 (the "Glenmark Alliance"). ● Strategic Marketing Alliance with Lannett Company. Inc. dated March 6, 2019 (the "Lannett-SunGen Product Alliance") ● Strategic Marketing Alliance with Lannett Company. Inc. dated April 9, 2019 (the "Lannett-Elite Product Alliance") The Precision Dose Agreement provides for the marketing and distribution, by Precision Dose and its wholly owned subsidiary, TAGI Pharma, of Phentermine 37.5mg tablets (launched in April 2011), Phentermine 15mg capsules (launched in April 2013), Phentermine 30mg capsules (launched in April 2013), Hydromorphone 8mg tablets (launched in March 2012), Naltrexone 50mg tablets (launched in September 2013) and certain additional products that require approval from the FDA which has not been received. Precision Dose will have the exclusive right to market these products in the United States and Puerto Rico and a non-exclusive right to market the products in Canada. Pursuant to the Precision Dose License Agreement, Elite received $200k at signing, and is receiving milestone payments and a license fee which is based on profits achieved from the commercial sale of the products included in the agreement. Revenue from the $200k payment made upon signing of the Precision Dose Agreement is being recognized over the life of the Precision Dose Agreement. The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 & 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts. These milestones have been determined to be substantive, with such determination being made by the Company after assessments based on the following: ● The Company's performance is required to achieve each milestone; and ● The milestones will relate to past performance, when achieved; and ● The milestones are reasonable relative to all of the deliverables and payment terms within the Precision Dose License Agreement. The license fees provided for in the Precision Dose Agreement are calculated as a percentage of net sales dollars realized from commercial sales of the related products. Net sales dollars consist of gross invoiced sales less those costs and deductions directly attributable to each invoiced sale, including, without limitation, cost of goods sold, cash discounts, Medicaid rebates, state program rebates, price adjustments, returns, short date adjustments, charge backs, promotions, and marketing costs. The rate applied to the net sales dollars to determine license fees due to the Company is equal to an amount negotiated and agreed to by the parties to the Precision Dose License Agreement, with the following significant factors, inputs, assumptions, and methods, without limitation, being considered by either or both parties: ● Assessment of the opportunity for each generic product in the market, including consideration of the following, without limitation: market size, number of competitors, the current and estimated future regulatory, legislative, and social environment for each generic product, and the maturity of the market; ● Assessment of various avenues for monetizing the generic products, including the various combinations of sites of manufacture and marketing options; ● Capabilities of each party with regards to various factors, including, one or more of the following: manufacturing resources, marketing resources, financial resources, distribution capabilities, ownership structure, personnel, assessment of operational efficiencies and stability, company culture and image; ● Stage of development of each generic product, all of which did not have FDA approval at the time of the discussions/negotiations and an assessment of the risks, probability, and time frame for achieving marketing authorizations from the FDA for the products; ● Assessment of consideration offered by Precision and other entities with whom discussions were conducted; and ● Comparison of the above factors among the various entities with whom the Company was engaged in discussions relating to the commercialization of the generic products. The SunGen Agreement provides for the research, development, sales and marketing of eight generic pharmaceutical products. Two of the products are classified as CNS stimulants (the "CNS Products"), two of the products are classified as beta blockers and the remaining four products consist of antidepressants, antibiotics and antispasmodics. To date, the Company has filed ANDAs with the FDA for the two CNS Products and one antibiotic identified in the SunGen Agreement. The Company received FDA approval of the ANDA filed for the first CNS Product in December 2018 and achieved commercial launch in April 2019, with such product being marketed pursuant to the Lannett Alliance. Under the terms of the SunGen Agreement, Elite and SunGen will share in the responsibilities and costs in the development of these products and will share substantially in the profits from sales. Upon approval, the know-how and intellectual property rights to the products will be owned jointly by Elite and SunGen. Three of the eight products will be jointly owned, three products will be owned by SunGen, with Elite having exclusive marketing rights and the remaining two products will be owned by Elite, with SunGen having exclusive marketing rights. Elite will manufacture and package all eight products on a cost-plus basis. The Glenmark Alliance, provides for the manufacture by Elite and marketing by Glenmark of identified generic products under license from Elite. In addition to the purchase prices for the products, Elite will receive license fees well in excess of 50% of gross profits. Gross profit is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. Glenmark will have semi-exclusive marketing rights to the ANDA approved generic product, phendimetrazine 35mg tablets, and exclusive marketing rights to generic Methadone HCl. Collectively, the brand products and their generic equivalents had total annual sales of approximately $33.6 million in 2017, according to Quintiles IMS Health data. The Agreement has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Glenmark to terminate with regard to a product on at least three months' prior written notice if it determines to stop marketing and selling such product, and it permits Elite to terminate with regard to a product if at any time after the first twelvemonths from the first commercial sale, the average license fee paid by Glenmark for such product is less than $100,000 for a six-month sales period. Pursuant to Lannett-SunGen Product Alliance with Lannett Company Inc. ("Lannett"), Lannett will be the exclusive U.S. marketer and distributor for two generic products co-developed and co-owned by Elite and SunGen – Amphetamine IR Tablets and a second product which is an extended release CNS stimulant that is currently under review by the FDA. Elite will manufacture and Lannett will purchase the products from Elite and then sell and distribute them. In addition to the purchase prices for the products, Elite will receive license fees in excess of 50% of net profits, which will be shared equally with SunGen, pursuant to the SunGen Agreement. The Lannett-SunGen Product Alliance has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months' prior written notice, and it permits Elite or Lannett to terminate with regard to a product if at any time after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period. In addition to manufacturing fees and license fees, Lannett will also pay a milestone, of $750,000 upon commercial launch of the extended release CNS stimulant product that is currently under review by the FDA. This milestone payment will be shared equally by Elite and SunGen, pursuant to the SunGen Agreement. The first commercial shipment of Amphetamine IR Tablets, a generic version of Adderall ® Pursuant to the Lannett-Elite Product Alliance, Lannett will be the exclusive U.S. marketer and distributor for Dantrolene Capsules. Elite will manufacture and Lannett will purchase Dantrolene Capsules from Elite and then sell and distribute them. In addition to the purchase prices for the products, Elite will receive license fees in excess of 50% of net profits. Net profits is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. The Lannett-Elite Product Alliance has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months' prior written notice and it permits Elite or Lannett to terminate with regard to a product if at any time after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period.

Related Party Agreements with M

Related Party Agreements with Mikah Pharma LLC	9 Months Ended
	Dec. 31, 2019
Mikah Pharma LLC [Member]
RELATED PARTY AGREEMENTS WITH MIKAH PHARMA LLC	NOTE 20. RELATED PARTY AGREEMENTS WITH MIKAH PHARMA LLC Pursuant to an asset acquisition, on May 17, 2017, Elite Labs, executed an assignment agreement with Mikah, pursuant to which the Company acquired all rights, interests, and obligations under a supply and distribution agreement (the "Reddy's Distribution Agreement") with Dr. Reddy's Laboratories, Inc. ("Dr. Reddy's") originally entered into by Mikah on May 7, 2017 and relating to the supply, sale and distribution of generic Trimipramine Maleate Capsules 25mg, 50mg and 100mg ("Trimipramine"). On May 22, 2017, the Company executed an assignment agreement with Mikah, pursuant to which the Company acquired all rights, interests and obligations under a manufacturing and supply agreement with Epic originally entered into by Mikah on June 30, 2015 and relating to the manufacture and supply of Trimipramine (the "Epic Trimipramine Manufacturing Agreement"). Pursuant to this agreement, Epic manufactured Trimipramine under license from Elite. In September 2018, Elite successfully transferred manufacturing of Trimipramine to the Northvale Facility, resulting in the irrelevance of the Epic Trimipramine Manufacturing Agreement. Trimipramine is currently manufactured by Elite. Mikah is owned by Nasrat Hakim, the CEO, President and Chairman of the Board of the Company. The Reddy's Distribution Agreement was concluded by mutual consent in August 2018. Trimipramine is one of the products included in the Glenmark Strategic Alliance and is currently marketed and distributed by Glenmark. On December 3, 2018, the Company executed a development agreement with Mikah, pursuant to which Mikah and the Company will collaborate to develop and commercialize generic products including formulation development, analytical method development, bioequivalence studies and manufacture of development batches of generic products. The Company received a total of $480,000 from Mikah, $150,000 and $330,000 in January and September of 2019, respectively, as an advance payment for the purchase of pharmaceutical materials relating to future product development conducted pursuant to this agreement. This amount was recorded as a deposit and contained within the customer deposits financial statement line item on the condensed consolidated balance sheet. As of the date of this report, the Company has purchased raw materials with an aggregate cost of $452,348 pursuant to this agreement. As of December 31, 2019, the balance of the customer deposit from Mikah was $55,653 and was included in the financial statement line of customer deposits on the accompanying condensed consolidated balance sheet.

Other Income - Proceeds From Sa

Other Income - Proceeds From Sale of ANADs	9 Months Ended
	Dec. 31, 2019
Collaborative Agreement with Sungen Pharma LLC [Abstract]
OTHER INCOME - PROCEEDS FROM SALE OF ANDAs	NOTE 21. OTHER INCOME – PROCEEDS FROM SALE OF ANDAs Sale of ANDAs for Oxycodone Hydrochloride and Acetaminophen, USP CII (generic version of Percocet®) Approved ANDAs for a generic version of Percocet ® Sale of ANDAs for Hydrocodone bitartrate and acetaminophen tablets USP CII (generic version of Norco) Approved ANDAs for a generic version of Norco ®

Subsequent Events

Subsequent Events	9 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 22. SUBSEQUENT EVENTS The Company has evaluated subsequent events from the condensed consolidated balance sheet date through February 10, 2020. The following are material subsequent events: Common Stock issued and sold pursuant to the Lincoln Park Purchase Agreement Subsequent to December 31, 2019 and up to February 4, 2020 (the latest practicable date), a total of 5,337,102 shares of Common Stock were issued to Lincoln Park, with such shares consisting of 5,265,484 purchase shares and 71,618 additional commitment shares. Total proceeds from these transactions was $517,037. Sale of ANDA for Hydromorphone HCl oral tablet – 8mg On February 3, 2020, Elite sold the ANDA for generic Hydromorphone HCl 8mg tablet to Nostrum for cash consideration totaling $300,000. The carrying value for the asset related to the ANDA was $0.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") and in conformity with the instructions on Form 10-Q and Rule 8-03 of Regulation S-X and the related rules and regulations of the Securities and Exchange Commission ("SEC"). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Elite Laboratories, Inc. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, which are, in the opinion of management, necessary for a fair presentation of such statements. The results of operations for the three and nine months ended December 31, 2019 are not necessarily indicative of the results that may be expected for the entire year.
Going Concern	Going Concern At December 31, 2019, the Company had unrestricted cash balances totaling $1,870,080. The Company has incurred losses and negative cash flows from operations, including operating income of $691,195 and loss of $2,637,130 for the three months ended December 31, 2019 and 2018, and operating losses of $911,042 and $7,148,496 for the nine months ended December 31, 2019 and 2018, respectively. In addition, overall working capital, defined as current assets minus current liabilities decreased by $654,482 as of December 31, 2019. Based on the foregoing, the Company has determined that there did appear to be evidence of substantial doubt of its ability to continue as a going concern. To continue as a going concern, the Company will need to do some or all of the following, without limitation: obtain additional financing, increase sales of existing products, bring additional products in the pipeline to market and/or reduce expenses. The successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements included herein do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.
Segment Information	Segment Information Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC 280"), Segment Reporting The Company has determined that its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Applications ("ANDA") and products whose marketing approvals were secured via a New Drug Application ("NDA"). ANDA products are referred to as generic pharmaceuticals and NDA products are referred to as branded pharmaceuticals. There are currently no intersegment revenues. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company's unaudited condensed consolidated financial statements. Please see Note 15 for further details.
Revenue Recognition	Revenue Recognition The Company generates revenue from the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, commercialization of products either by license and the collection of royalties, or through the manufacture of formulations and the development of new products and the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations. The Company also generates revenue through its focus on the development of various types of drug products, including branded drug products which require NDAs. Under ASC 606, Revenue from Contacts with Customers
Nature of goods and services	Nature of goods and services The following is a description of the Company's goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable: a) Manufacturing Fees The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if, and when, the products are approved. These products include products using controlled-release drug technology and products utilizing abuse deterrent technologies. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release and abuse deterrent pharmaceutical products. The Company recognizes revenue when the customer obtains control of the Company's product based on the contractual shipping terms of the contract. Revenue on product are presented gross because the Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer. b) License Fees The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales. If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations. The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will not recognize revenue from the milestone until there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event. Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company's contracts contained a significant financing component as of December 31, 2019. In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer's products occurs.
Disaggregation of revenue	Disaggregation of revenue In the following table, revenue is disaggregated by type of revenue generated by the Company and timing of revenue recognition. The table also includes a reconciliation of the disaggregated revenue with the reportable segments: For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 NDA: Licensing fees $ 250,000 $ 250,000 $ 750,000 $ 750,000 Total NDA revenue 250,000 250,000 750,000 750,000 ANDA: Manufacturing fees $ 3,754,721 $ 2,108,487 $ 10,851,425 $ 4,456,832 Licensing fees 1,050,392 335,479 1,447,915 1,017,881 Total ANDA revenue 4,805,113 2,443,966 12,299,340 5,474,713 Total revenue $ 5,055,113 $ 2,693,966 $ 13,049,340 $ 6,224,713
Collaborative Arrangements	Collaborative Arrangements Contracts are considered to be collaborative arrangements when they satisfy the following criteria defined in ASC 808, Collaborative Arrangements ● The parties to the contract must actively participate in the joint operating activity; and, ● The joint operating activity must expose the parties to the possibility of significant risk and rewards, based on whether or not the activity is successful. The Company entered into a sales and distribution licensing agreement with Epic Pharma LLC, ("Epic") dated June 4, 2015 (the "2015 Epic License Agreement"), which has been determined to satisfy the criteria for consideration as a collaborative agreement, and is accounted for accordingly, in accordance with GAAP. The Company entered into a Master Development and License Agreement with SunGen Pharma LLC dated August 24, 2016 (the "SunGen Agreement"), which has been determined to satisfy the criteria for consideration as a collaborative agreement, and is accounted for accordingly, in accordance with GAAP.
Cash	Cash The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market instruments. The Company places its cash and cash equivalents with high-quality, U.S. financial institutions and, to date has not experienced losses on any of its balances.
Restricted Cash	Restricted Cash As of December 31, 2019, and March 31, 2019, the Company had $403,575 and $398,125 of restricted cash, respectively, related to debt service reserve in regard to the New Jersey Economic Development Authority ("NJEDA") bonds (see Note 5).
Accounts Receivable	Accounts Receivable Accounts receivable are comprised of balances due from customers, net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances.
Inventory	Inventory Inventory is recorded at the lower of cost or market on specific identification by lot number basis.
Long-Lived Assets	Long-Lived Assets The Company periodically evaluates the fair value of long-lived assets, which include property and equipment and intangibles, whenever events or changes in circumstances indicate that its carrying amounts may not be recoverable. Property and equipment are stated at cost. Depreciation is provided on the straight-line method based on the estimated useful lives of the respective assets which range from three to forty years. Major repairs or improvements are capitalized. Minor replacements and maintenance and repairs which do not improve or extend asset lives are expensed currently. Upon retirement or other disposition of assets, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is recognized in income.
Intangible Assets	Intangible Assets The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. Costs to acquire indefinite lived intangible assets, such as costs related to ANDAs are capitalized accordingly. The Company tests its intangible assets for impairment at least annually (as of March 31st) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company's expected future cash flows; a sustained, significant decline in the Company's stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company's segments; unanticipated competition; and slower growth rates. As of December 31, 2019, the Company did not identify any indicators of impairment. Please also see Note 4 for further details on intangible assets.
Research and Development	Research and Development Research and development expenditures are charged to expense as incurred.
Contingencies	Contingencies Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company's condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future.
Warrants and Preferred Shares	Warrants and Preferred Shares The accounting treatment of warrants and preferred share series issued is determined pursuant to the guidance provided by ASC 470, Debt Distinguishing Liabilities from Equity Derivatives and Hedging
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation In accordance with the Company's Director compensation policy and certain employment contracts, director's fees and a portion of employee's salaries are to be paid via the issuance of shares of the Company's common stock, in lieu of cash, with the valuation of such share being calculated on a quarterly basis and equal to the average closing price of the Company's common stock.
Earnings (Loss) Per Share Attributable to Common Shareholders'	Earnings (Loss) Per Share Attributable to Common Shareholders' The Company follows ASC 260, Earnings Per Share The following is the computation of earnings (loss) per share applicable to common shareholders for the periods indicated: For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 Numerator Net loss attributable to common shareholders – basic $ (1,860,680 ) $ (2,344,318 ) $ (3,176,719 ) $ (6,615,616 ) Effect of dilutive instrument on net loss - (380,976 ) - (807,347 ) Net loss attributable to common shareholders - diluted $ (1,860,680 ) $ (2,725,924 ) $ (3,176,719 ) $ (7,422,963 ) Denominator Weighted average shares of common stock outstanding - basic 829,394,203 819,412,807 828,446,951 811,603,678 Dilutive effect of stock options, warrants and convertible securities - 56,074 - 56,074 Weighted average shares of common stock outstanding – diluted 829,394,203 819,468,881 828,466,951 811,659,752 Net loss per share attributable to common shareholders Basic $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.01 ) Diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.01 )
Fair Value of Financial Instruments	Fair Value of Financial Instruments ASC 820, Fair Value Measurements and Disclosures ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described as follows: ● Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. ● Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. ● Level 3 – Inputs that are unobservable for the asset or liability. Measured on a Recurring Basis The following table presents information about our liabilities measured at fair value on a recurring basis, aggregated by the level in the fair value hierarchy within which those measurements fell: Fair Value Measurement Using Amount at Fair Value Level 1 Level 2 Level 3 December 31 2019 Liabilities Derivative financial instruments – warrants $ 5,078,525 $ - $ - $ 5,078,525 March 31, 2019 Liabilities Derivative financial instruments – warrants $ 2,487,830 $ - $ - $ 2,487,830 See Note 11, for specific inputs used in determining fair value. The carrying amounts of the Company's financial assets and liabilities, such as cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate their fair values because of the short maturity of these instruments. Based upon current borrowing rates with similar maturities the carrying value of long-term debt approximates fair value. Non-Financial Assets that are Measured at Fair Value on a Non-Recurring Basis Non-financial assets such as intangible assets, and property and equipment are measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets in the periods presented.
Treasury Stock	Treasury Stock The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of shareholders' deficit.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-02, Leases (Topic 842) On April 1, 2019, the Company adopted Topic 842 using the modified retrospective basis with a cumulative-effect adjustment at the beginning of the period of adoption and therefore did not revise prior period information or disclosure. Further, the Company elected the package of practical expedients upon transition that allows the Company not to reassess the lease classification for expired and existing leases, whether initial direct costs qualify for capitalization for any expired or existing leases or whether any expired contracts are or contain leases. The adoption of ASU 2016-02 resulted in the recognition of operating leases and lease liabilities of approximately $0.6 million on the condensed consolidated balance sheet as of April 1, 2019. The operating leases and lease liabilities relate to a real estate lease. The impact of the adoption of Topic 842 on the accompanying condensed consolidated balance sheet as of April 1, 2019 was as follows: March 31, Adoption Adjustment April 1, Operating lease - right of use $ - $ 554,088 $ 554,088 Deferred rent liability $ 13,022 $ (13,022 ) $ - Lease obligation - operating lease $ - $ 191,817 $ 191,817 Lease obligation - operating lease, net of current portion $ - $ 375,293 $ 375,293 See additional lease disclosures in Note 9.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments - Credit Losses Financial Instruments - Credit Losses (Topic 326), Targeted Transition Relief Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842). Codification Improvements to Topic 326, Financial Instruments – Credit Losses. Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our condensed consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of disaggregation of revenue	For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 NDA: Licensing fees $ 250,000 $ 250,000 $ 750,000 $ 750,000 Total NDA revenue 250,000 250,000 750,000 750,000 ANDA: Manufacturing fees $ 3,754,721 $ 2,108,487 $ 10,851,425 $ 4,456,832 Licensing fees 1,050,392 335,479 1,447,915 1,017,881 Total ANDA revenue 4,805,113 2,443,966 12,299,340 5,474,713 Total revenue $ 5,055,113 $ 2,693,966 $ 13,049,340 $ 6,224,713
Schedule of earnings (loss) per share applicable to common shareholders	For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 Numerator Net loss attributable to common shareholders – basic $ (1,860,680 ) $ (2,344,318 ) $ (3,176,719 ) $ (6,615,616 ) Effect of dilutive instrument on net loss - (380,976 ) - (807,347 ) Net loss attributable to common shareholders - diluted $ (1,860,680 ) $ (2,725,924 ) $ (3,176,719 ) $ (7,422,963 ) Denominator Weighted average shares of common stock outstanding - basic 829,394,203 819,412,807 828,446,951 811,603,678 Dilutive effect of stock options, warrants and convertible securities - 56,074 - 56,074 Weighted average shares of common stock outstanding – diluted 829,394,203 819,468,881 828,466,951 811,659,752 Net loss per share attributable to common shareholders Basic $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.01 ) Diluted $ (0.00 ) $ (0.00 ) $ (0.00 ) $ (0.01 )
Schedule of liabilities measured at fair value on a recurring basis	Fair Value Measurement Using Amount at Fair Value Level 1 Level 2 Level 3 December 31 2019 Liabilities Derivative financial instruments – warrants $ 5,078,525 $ - $ - $ 5,078,525 March 31, 2019 Liabilities Derivative financial instruments – warrants $ 2,487,830 $ - $ - $ 2,487,830
Schedule of condensed consolidated balance sheet	March 31, Adoption Adjustment April 1, Operating lease - right of use $ - $ 554,088 $ 554,088 Deferred rent liability $ 13,022 $ (13,022 ) $ - Lease obligation - operating lease $ - $ 191,817 $ 191,817 Lease obligation - operating lease, net of current portion $ - $ 375,293 $ 375,293

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Dec. 31, 2019
Inventory Disclosure [Abstract]
Schedule of inventory	December 31, March 31, Finished goods $ 55,521 $ 575,699 Work-in-progress 238,052 189,069 Raw materials 3,516,828 3,750,955 3,810,401 4,515,723 Less: Inventory reserve - - $ 3,810,401 $ 4,515,723

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	December 31, March 31, Land, building and improvements $ 5,260,523 $ 5,260,523 Laboratory, manufacturing, warehouse and transportation equipment 12,135,950 12,078,340 Office equipment and software 373,601 373,601 Furniture and fixtures 383,103 383,103 18,153,177 18,095,567 Less: Accumulated depreciation (10,634,174 ) (9,651,718 ) $ 7,519,003 $ 8,443,849

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	December 31 2019 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 465,684 $ - $ - $ - $ 465,684 ANDA acquisition costs Indefinite 6,168,351 - - - 6,168,351 $ 6,634,035 $ - $ - $ - $ 6,634,035 March 31, 2019 Estimated Gross Useful Carrying Accumulated Net Book Life Amount Additions Reductions Amortization Value Patent application costs * $ 465,684 $ - $ - $ - $ 465,684 ANDA acquisition costs Indefinite 7,247,317 - (1,078,966 ) - 6,168,351 $ 7,713,001 $ - $ (1,078,966 ) $ - $ 6,634,035

NJEDA Bonds (Tables)

NJEDA Bonds (Tables)	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of bonds payable liability	December 31, March 31, Gross bonds payable NJEDA Bonds - Series A Notes $ 1,575,000 $ 1,670,000 Less: Current portion of bonds payable (prior to deduction of bond offering costs) (105,000 ) (95,000 ) Long-term portion of bonds payable (prior to deduction of bond offering costs) $ 1,470,000 $ 1,575,000 Bond offering costs $ 354,454 $ 354,453 Less: Accumulated amortization (203,221 ) (192,591 ) Bond offering costs, net $ 151,233 $ 161,862 Current portion of bonds payable - net of bond offering costs Current portions of bonds payable $ 105,000 $ 95,000 Less: Bonds offering costs to be amortized in the next 12 months (14,178 ) (14,178 ) Current portion of bonds payable, net of bond offering costs $ 90,822 $ 80,822 Long term portion of bonds payable - net of bond offering costs Long term portion of bonds payable $ 1,470,000 $ 1,575,000 Less: Bond offering costs to be amortized subsequent to the next 12 months (137,055 ) (147,685 ) Long term portion of bonds payable, net of bond offering costs $ 1,332,945 $ 1,427,315

Loans Payable (Tables)

Loans Payable (Tables)	9 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Schedule of loans payable	December 31, March 31, Equipment and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between March 2019 and July 2024 $ 886,817 $ 1,272,298 Less: Current portion of loans payable (356,137 ) (573,029 ) Long-term portion of loans payable $ 530,480 $ 699,269

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of lease assets and liabilities	Lease Classification As of Assets Operating Operating lease – right to use asset $ 412,063 Total leased assets $ 412,063 Liabilities Current Operating Lease obligation – operating lease $ 203,984 Long-term Operating Lease obligation – operating lease, net of current portion 221,166 Total lease liabilities $ 425,150
Schedule of the future minimum rental payments	Years ending March 31, Amount 2020 — Remaining $ 55,986 2021 225,063 2022 171,315 Total future minimum lease payments 452,634 Less: interest (27,214 ) Present value of lease payments $ 425,150
Schedule of weighted-average remaining lease term and the weighted-average discount rate	Lease Term and Discount Rate December 31, Remaining lease term (years) Operating leases 2.0 Discount rate Operating leases 6 %

Preferred Stock (Tables)

Preferred Stock (Tables)	9 Months Ended
	Dec. 31, 2019
Schedule of key assumptions used in the monte carlo simulation	April 28, 2017 Fair value of the Company's common stock $ 0.1521 Initial exercise price $ 0.1521 Number of Series J Preferred issued 24.0344 Fully diluted shares outstanding as of measurement date 923,392,780 Risk-free rate 2.30 % Volatility 90.00 % Shareholder approval threshold $ 0.1521 Probability of approval is ending stock price is greater than threshold - midpoint 82.50 % Probability of approval is ending stock price is greater than threshold - midpoint 17.50 % Trials 200,000
Series J Convertible preferred stock [Member]
Schedule of authorized, issued and outstanding shares, along with carrying value and change in value	Shares authorized 50 Shares outstanding 24.0344 Par value $ 0.01 Stated value $ 1,000,000 Conversion price $ 0.1521 Common shares to be issued upon redemption 158,017,321 Carrying value of Series J convertible preferred stock $ 13,903,960

Derivative Financial Instrume_2

Derivative Financial Instruments - Warrants (Tables)	9 Months Ended
	Dec. 31, 2019
Derivative Liabilities Warrants Disclosure [Abstract]
Schedule of warrant activity	December 31 2019 March 31, 2019 Warrant Shares Weighted Avg. Exercise Price Warrant Shares Weighted Avg. Exercise Price Balance at beginning of period 79,008,661 $ 0.1521 79,008,661 $ 0.1521 Warrants granted pursuant to the issuance of Series J convertible preferred shares - - - - Warrants exercised, forfeited and/or expired, net - - - - Balance at end of period 79,008,661 $ 0.1521 79,008,661 $ 0.1521
Schedule of key assumptions used in the monte carlo simulation	March 31, Fair value of the Company's common stock $ 0.9900 Initial exercise price $ 0.1521 Number of common warrants 79,008,661 Fully diluted shares outstanding as of measurement date 824,946,559 Warrant term (in years) 8.08 Risk-free rate 2.35 % Volatility 90.00 % Shareholder approval threshold $ 0.1580 Probability of approval is ending stock price is greater than threshold - midpoint 82.50 % Probability of approval is ending stock price is greater than threshold - midpoint 17.50 % Trials 100,000 Fair value of derivative financial instruments - warrants $ 2,487,830
Schedule of the fair value of the warrants issued	December 31, Fair value of the Company's common stock $ 0.0925 Volatility 83.89 % Initial exercise price $ 0.1521 Warrant term (in years) 7.3 Risk free rate 1.83 %
Schedule of changes in warrants measured at fair value on a recurring basis	Outstanding at March 31, 2019 $ 2,487,830 Change in fair value of derivative financial instruments - warrants 2,590,695 Balance at December 31, 2019 $ 5,078,525

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of stock option plan	Weighted Average Shares Weighted Remaining Contractual Aggregate Underlying Options Exercise Term (in years) Intrinsic Outstanding at April 1, 2019 6,158,000 $ 0.15 5.0 $ 87,330 Forfeited and expired (283,000 ) $ 0.15 7.8 $ - Outstanding at December 31, 2019 5,875,000 $ 0.14 4.0 $ - Exercisable at December 31 2019 5,541,668 $ 0.14 4.0 $ 67,500

Segment Results (Tables)

Segment Results (Tables)	9 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Schedule of selected information for reportable segments	For the Three Months Ended For the Nine Months Ended December 31, 2019 2018 2019 2018 Operating Income (Loss) by Segment ANDA $ 2,431,906 $ (582,822 ) $ 2,538,560 $ (1,129,324 ) NDA 135,500 (744,393 ) 407,245 (1,250,420 ) $ 2,567,406 $ (1,327,215 ) $ 2,945,805 $ (2,379,744 )
Schedule of operating loss by segment to (loss) income from operations	For the Three Months Ended For the Nine Months Ended 2019 2018 2019 2018 Operating income (loss) by segment $ 2,567,406 $ (1,327,215 ) $ 2,945,805 $ (2,379,744 ) Corporate unallocated costs (739,790 ) (667,002 ) (1,740,579 ) (3,111,346 ) Interest income 2,334 1,733 10,667 4,570 Interest expense (94,515 ) (89,897 ) (283,649 ) (279,037 ) Depreciation and amortization expense (323,368 ) (321,164 ) (986,001 ) (891,390 ) Non-cash items (213,052 ) (321,749 ) (532,267 ) (766,016 ) Change in fair value of derivative instruments – warrants (3,059,695 ) 380,976 (2,590,695 ) 807,347 Loss from operations $ (1,860,680 ) $ (2,344,318 ) $ (3,176,719 ) $ (6,615,616 )

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 5,055,113	$ 2,693,966	$ 13,049,340	$ 6,224,713
NDA [Member]
Revenues	250,000	250,000	750,000	750,000
NDA [Member] | Licensing fees [Member]
Revenues	250,000	250,000	750,000	750,000
ANDA [Member]
Revenues	4,805,113	2,443,966	12,299,340	5,474,713
ANDA [Member] | Licensing fees [Member]
Revenues	1,050,392	335,479	1,447,915	1,017,881
ANDA [Member] | Manufacturing fees [Member]
Revenues	$ 3,754,721	$ 2,108,487	$ 10,851,425	$ 4,456,832

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Numerator
Net loss attributable to common shareholders - basic	$ (1,860,680)	$ (2,725,924)	$ (3,176,719)	$ (6,615,616)
Effect of dilutive instrument on net loss		(380,976)		(807,347)
Net loss attributable to common shareholders - diluted	$ (1,860,680)	$ (2,725,924)	$ (3,176,719)	$ (7,422,963)
Denominator
Weighted average shares of common stock outstanding - basic	829,394,203	819,412,807	828,466,951	811,603,678
Dilutive effect of stock options, warrants and convertible securities		56,074		56,074
Weighted average shares of common stock outstanding - diluted	829,394,203	819,468,881	828,466,951	811,659,752
Net income (loss) per share attributable to common shareholders
Basic	$ 0	$ 0	$ 0	$ (0.01)
Diluted	$ 0	$ 0	$ 0	$ (0.01)

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Derivative financial instruments - warrants	$ 5,078,525	$ 2,487,830
Level 1 [Member]
Derivative financial instruments - warrants
Level 2 [Member]
Derivative financial instruments - warrants
Level 3 [Member]
Derivative financial instruments - warrants	$ 5,078,525	$ 2,487,830

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - USD ($)	Apr. 03, 2019	Apr. 02, 2019	Mar. 31, 2019
Operating lease - right of use		$ 554,088
Deferred rent liability			$ 13,022
Lease obligation - operating lease		191,817
Lease obligation - operating lease, net of current portion		$ 375,293
Adoption Adjustment [Member]
Operating lease - right of use	$ 554,088
Deferred rent liability	(13,022)
Lease obligation - operating lease	191,817
Lease obligation - operating lease, net of current portion	$ 375,293

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Summary of Significant Accounting Policies (Textual)
Restricted cash	$ 403,575		$ 403,575		$ 398,125
Unrestricted cash balance	1,870,080		1,870,080
Operating losses	691,195	$ (2,637,130)	(911,042)	$ (7,148,496)
Working capital	654,482		654,482
Operating leases and lease liabilities	$ 425,150		$ 425,150
Accounting Standards Update 2016-02 [Member]
Summary of Significant Accounting Policies (Textual)
Operating leases and lease liabilities					$ 600,000
Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful lives of property and equipment			40 years
Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Estimated useful lives of property and equipment			3 years

Inventory (Details)

Inventory (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Inventory Disclosure [Abstract]
Finished goods	$ 55,521	$ 575,699
Work-in-progress	238,052	189,069
Raw materials	3,516,828	3,750,955
Inventory, gross	3,810,401	4,515,723
Less: Inventory reserve
Inventory, net	$ 3,810,401	$ 4,515,723

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 18,153,177	$ 18,095,567
Less: Accumulated depreciation	(10,634,174)	(9,651,718)
Property and equipment, net	7,519,003	8,443,849
Land, building and improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,260,523	5,260,523
Laboratory, manufacturing, warehouse and transportation equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	12,135,950	12,078,340
Office equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	373,601	373,601
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 383,103	$ 383,103

Property and Equipment, Net (_2

Property and Equipment, Net (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Property and Equipment, Net (Textual)
Depreciation expense	$ 326,908	$ 317,618	$ 982,456	$ 931,180

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 6,634,035	$ 7,713,001
Additions
Reductions		(1,078,966)
Accumulated Amortization
Net Book Value	$ 6,634,035	$ 6,634,035
Patent application costs [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	0 Years	0 Years
Gross Carrying Amount	$ 465,684	$ 465,684
Additions
Reductions
Accumulated Amortization
Net Book Value	$ 465,684	$ 465,684
ANDA acquisition costs [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Life	Indefinite	Indefinite
Gross Carrying Amount	$ 6,168,351	$ 7,247,317
Additions
Reductions		(1,078,966)
Accumulated Amortization
Net Book Value	$ 6,168,351	$ 6,168,351

NJEDA Bonds (Details)

NJEDA Bonds (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Njeda Bonds [Line Items]
Less: Current portion of bonds payable (prior to deduction of bond offering costs)	$ (90,822)	$ (80,822)
Long-term portion of bonds payable (prior to deduction of bond offering costs)	1,332,945	1,427,315
NJEDA Bonds Current [Member]
Njeda Bonds [Line Items]
Bonds payable	105,000	95,000
Less: Bond offering costs to be amortized	(14,178)	(14,178)
Bonds payable, net of bond offering costs	90,822	80,822
NJEDA Bonds Non-Current [Member]
Njeda Bonds [Line Items]
Bonds payable	1,470,000	1,575,000
Less: Bond offering costs to be amortized	(137,055)	(147,685)
Bonds payable, net of bond offering costs	1,332,945	1,427,315
NJEDA Bonds Series A Notes [Member]
Njeda Bonds [Line Items]
NJEDA Bonds - Series A Notes	1,575,000	1,670,000
Less: Current portion of bonds payable (prior to deduction of bond offering costs)	(105,000)	(95,000)
Long-term portion of bonds payable (prior to deduction of bond offering costs)	1,470,000	1,575,000
Bond offering costs	354,454	354,453
Less: Accumulated amortization	(203,221)	(192,591)
Bond offering costs, net	$ 151,233	$ 161,862

NJEDA Bonds (Details Textual)

NJEDA Bonds (Details Textual) - NJEDA Bonds [Member] - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
NJEDA Bonds (Textual)
Amortization expense	$ 3,545	$ 3,544	$ 10,630	$ 10,636
Annual interest rate			6.50%

Loans Payable (Details)

Loans Payable (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Debt Disclosure [Abstract]
Equipment and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between March 2019 and July 2024	$ 886,817	$ 1,272,298
Less: Current portion of loans payable	(356,137)	(573,029)
Long-term portion of loans payable	$ 530,480	$ 699,269

Loans Payable (Details Textual)

Loans Payable (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Interest expense	$ 18,291	$ 28,025	$ 63,170	$ 86,765
Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	12.73%		12.73%
Maturity date	Jul. 31, 2024		Jul. 31, 2024
Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage	3.50%		3.50%
Maturity date	Mar. 31, 2019		Mar. 31, 2019

Related Party Secured Promiss_2

Related Party Secured Promissory Note with Mikah Pharma LLC (Details) - USD ($)	May 15, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Mar. 31, 2019
Interest expense, total		$ 94,514	$ 89,897	$ 283,649	$ 279,037
Secured Promissory Note [Member]
Interest rate percentage	15.00%
Principal amount	$ 1,200,000
Maturity date	Dec. 31, 2020
Interest rate	10.00%
Interest expense, total				30,000	$ 90,000
Accrued interest		$ 315,000		$ 315,000		$ 225,000

Deferred Revenue (Details)

Deferred Revenue (Details) - USD ($)	9 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Deferred Revenue (Textual)
Deferred revenues	$ 492,224	$ 1,252,223
Deferred revenues current component	430,000	1,013,333
Deferred revenues long-term component	$ 62,224	$ 238,890
Licensing Agreements [Member]
Deferred Revenue (Textual)
Deferred revenues term, description	Straight-line basis.
TAGI licensing agreement [Member]
Deferred Revenue (Textual)
Deferred revenues term, description	Fifteen-year term beginning in September 2010 and ending in August 2025.
Advance payment of deferred revenue	$ 200,000
Epic Collaborative Agreement [Member]
Deferred Revenue (Textual)
Deferred revenues term, description	Five-year term beginning in June 2015 and ending in May 2020.
Advance payment of deferred revenue	$ 5,000,000

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease - right to use asset	$ 412,063
Total leased assets	412,063
Lease obligation - operating lease	203,984
Lease obligation - operating lease, net of current portion	221,166
Total lease liabilities	$ 425,150

Commitments and Contingencies_3

Commitments and Contingencies (Details 1)	Dec. 31, 2019USD ($)
Years ending March 31,
2020 - Remaining	$ 55,986
2021	225,063
2022	171,315
Total future minimum lease payments	452,634
Less: interest	(27,214)
Present value of lease payments	$ 425,150

Commitments and Contingencies_4

Commitments and Contingencies (Details 2)	Dec. 31, 2019
Lease Term and Discount Rate
Remaining lease term (years) Operating leases	2 years
Discount rate operating leases	6.00%

Commitments and Contingencies_5

Commitments and Contingencies (Details Textual)	3 Months Ended		9 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Mar. 31, 2019USD ($)	Jul. 31, 2014a	Jul. 01, 2010a
Commitments and Contingencies (Textual)
Operating lease, terms			Lease includes an initial term, which expired on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021.
General and Administrative Expense [Member]
Commitments and Contingencies (Textual)
Rent expense | $	$ 18,296	$ 54,909	$ 128,072	$ 164,757
Other Noncurrent Liabilities [Member]
Commitments and Contingencies (Textual)
Other long-term liabilities | $	$ 34,916		$ 34,916		$ 33,383
Property Subject to Operating Lease [Member] | Warehouse [Member]
Commitments and Contingencies (Textual)
Building floor space | a							15,000
July 2014 Modification Agreement [Member] | Property Subject to Operating Lease [Member] | Warehouse [Member]
Commitments and Contingencies (Textual)
Building floor space | a						35,000

Preferred Stock (Details)

Preferred Stock (Details) - Series J Convertible preferred stock [Member]	1 Months Ended
	Apr. 28, 2017$ / sharesshares
Fair value of the Company's common Stock | $ / shares	$ 0.1521
Initial exercise price | $ / shares	$ 0.1521
Number of Series J Preferred issued | shares	24.0344
Fully diluted shares outstanding as of measurement date | shares	923,392,780
Shareholder approval threshold | $ / shares	0.1521
Trials | shares	200,000
Risk-free rate [Member]
Fair value assumptions percentage	2.30%
Volatility [Member]
Fair value assumptions percentage	90.00%
Probability of approval is ending stock price is greater than threshold - midpoint [Member] | Maximum [Member]
Fair value inputs probability percentage	82.50%
Probability of approval is ending stock price is greater than threshold - midpoint [Member] | Minimum [Member]
Fair value inputs probability percentage	17.50%

Preferred Stock (Details 1)

Preferred Stock (Details 1) - USD ($)	Dec. 31, 2019	Mar. 31, 2019
Equity [Abstract]
Shares authorized	50	50
Shares outstanding	24.0344	24.0344
Par value		$ 0.01
Stated value		$ 1,000,000
Conversion price		$ 0.1521
Common shares to be issued upon redemption		158,017,321
Carrying value of Series J convertible preferred stock		$ 13,903,960

Preferred Stock (Details Textua

Preferred Stock (Details Textual) - USD ($)	9 Months Ended
	Dec. 31, 2019	Dec. 04, 2019	Mar. 31, 2019	Apr. 28, 2017
Mezzanine Equity (Textual)
Preferred stock share authorized	50		50
Preferred stock shares issued	24.0344		24.0344
Preferred stock shares outstanding	24.0344		24.0344
Convertible preferred stock par value per share			$ 0.01
Convertible preferred stock stated value			$ 1,000,000
Preferred stock par value	$ 0.01		$ 0.01
Carrying value of Series J convertible preferred stock	$ 13,903,960
Increased number of common stock shares authorized	1,445,000,000		995,000,000
Maximum [Member]
Mezzanine Equity (Textual)
Increased number of common stock shares authorized		1,445,000,000
Minimum [Member]
Mezzanine Equity (Textual)
Increased number of common stock shares authorized		995,000,000
Series J Convertible preferred stock [Member]
Mezzanine Equity (Textual)
Convertible preferred stock par value per share	$ 0.01
Convertible preferred stock stated value	$ 1,000,000
Preferred stock conversion price per share	$ 0.1521
Shares of common stock	158,017,321
Percentage of dividend rate	20.00%
Fair value measured				$ 13,903,960
Series J Convertible preferred stock [Member] | Nasrat Hakim [Member]
Mezzanine Equity (Textual)
Warrants to purchase	79,008,661			79,008,661
Shares of common stock per share	$ 0.1521			$ 0.1521

Derivative Financial Instrume_3

Derivative Financial Instruments - Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Derivative Liabilities Warrants Disclosure [Abstract]
Warrant Shares, Balance at beginning of period	79,008,661	79,008,661
Warrant Shares, Warrants granted pursuant to the issuance of Series J convertible preferred shares
Warrant Shares, Warrants exercised, forfeited and/or expired, net
Warrant Shares, Balance at end of period	79,008,661	79,008,661
Weighted Average Exercise Price, Balance at beginning of period	$ 0.1521	$ 0.1521
Weighted Average Exercise Price, Warrants granted pursuant to the issuance of Series J convertible preferred shares
Weighted Average Exercise Price, Warrants exercised, forfeited and/or expired, net
Weighted Average Exercise Price, Balance at end of period	$ 0.1521	$ 0.1521

Derivative Financial Instrume_4

Derivative Financial Instruments - Warrants (Details 1) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Risk-free rate	1.83%
Volatility	83.89%
Warrant [Member]
Fair value of the company's common stock		$ 0.9900
Initial exercise price		$ 0.1521
Number of common warrants		79,008,661
Fully diluted shares outstanding as of measurement date		824,946,559
Warrant term (in years)		8 years 29 days
Risk-free rate		2.35%
Volatility		90.00%
Shareholder approval threshold		0.1580
Trials		100,000
Fair value of derivative financial instruments - warrants		$ 2,487,830
Warrant [Member] | Maximum [Member]
Probability of approval is ending stock price is greater than threshold - midpoint		82.50%
Warrant [Member] | Minimum [Member]
Probability of approval is ending stock price is greater than threshold - midpoint		17.50%

Derivative Financial Instrume_5

Derivative Financial Instruments - Warrants (Details 2) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019	Mar. 31, 2017
Volatility (based on the Company's historical volatility)	83.89%
Estimated life (in years)	7 years 3 months 19 days
Risk free interest rate (based on 1-year treasury rate)	1.83%
Warrant [Member]
Fair value of the Company's common stock			$ 0.0925
Volatility (based on the Company's historical volatility)		90.00%
Initial exercise price			$ 0.1521
Risk free interest rate (based on 1-year treasury rate)		2.35%

Derivative Financial Instrume_6

Derivative Financial Instruments - Warrants (Details 3) - Level 3 [Member] - Warrants [Member]	9 Months Ended
	Dec. 31, 2019USD ($)
Balance as of March 31, 2019	$ 2,487,830
Change in fair value of derivative financial instruments - warrants	(2,590,695)
Balance at September 30, 2019	$ 5,078,525

Derivative Financial Instrume_7

Derivative Financial Instruments - Warrants (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Apr. 28, 2017	Dec. 31, 2019
Derivative Financial Instruments - Warrants (Textual)
Warrant expiration period	10 years	7 years
Fair Value of Warrants, Description		The fair value of the warrants issued by the Company pursuant to the issuance of Series J convertible preferred shares (79,008,661 warrant shares) was calculated using a Black-Scholes model instead of a Monte Simulation because the probability with the shareholder approval provisions was no longer a factor. The following assumptions were used in the Black-Scholes model to calculate the fair value of warrants issued by the Company pursuant to the issuance of Series J convertible preferred shares (79,008,661 warrant shares).
Series J Warrant [Member]
Derivative Financial Instruments - Warrants (Textual)
Initial exercise price	$ 0.1521
Nasrat Hakim [Member]
Derivative Financial Instruments - Warrants (Textual)
Warrant shares	79,008,661
Nasrat Hakim [Member] | Series J Convertible preferred stock [Member]
Derivative Financial Instruments - Warrants (Textual)
Conversion of stock, shares issued	23.0344
Warrant shares	79,008,661
Conversion of stock, shares converted	158,017,321
Fair value of the warrants	$ 6,474,674

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)	Jun. 05, 2017	May 01, 2017	Apr. 10, 2014	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Proceeds from issuance stock				$ 806,987	$ 1,669,829
Lincoln Park [Member]
Class of Stock [Line Items]
Shares, issued				40,000,000
Purchase of common stock, Shares				8,895,233	17,642,083
Purchase of common stock, amount				$ 806,987	$ 1,669,829
Common stock additional shares issued				111,778	231,295
Lincoln Park Capital Fund, LLC [Member]
Class of Stock [Line Items]
Shares, issued	40,000,000	5,540,551	40,000,000	1,928,641
Additional shares issued				1,928,641
Proceeds from issuance stock				$ 27,000,000
Common stock shares		500,000
Purchase of common stock increasing shares per purchase		1,000,000
Maximum common stock value directed to purchase		$ 1,000,000
Purchase of common stock, Shares				110,600,000
Common stock additional shares issued		5,540,551
Stock issued during period, shares, issued for capital purchase agreement				3,200,000
Common stock weighted average price percent		4.99%
Description of sale of stock			The Company entered into a Purchase Agreement (the "Lincoln Park Purchase Agreement" and/or "Purchase Agreement") and a Registration Rights Agreement (the "Registration Rights Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"). Pursuant to the terms of the Purchase Agreement, Lincoln Park agreed to purchase from the Company up to $40 million of common stock (subject to certain limitations) from time to time over a 36-month period that ended June 1, 2017. Pursuant to the terms of the Registration Rights Agreement, the Company filed with the SEC registration statements to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase Agreement.

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	9 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Equity [Abstract]
Shares Underlying Options, Outstanding at Beginning | shares	6,158,000
Shares Underlying Options, Forfeited and expired | shares	(283,000)
Shares Underlying Options, Outstanding at Ending | shares	5,875,000
Shares Underlying Options, Exercisable | shares	5,541,668
Weighted Average Exercise Price, Outstanding at Beginning	$ 0.15
Weighted Average Exercise Price, Options Forfeited and expired	0.15
Weighted Average Exercise Price, Outstanding at Ending	0.14
Weighted Average Exercise Price, Options Exercisable	$ 0.14
Weighted Average Remaining Contractual Term (in years), Outstanding at Beginning	5 years
Weighted Average Remaining Contractual Term, Forfeited and expired	7 years 9 months 18 days
Weighted Average Remaining Contractual Term (in years), Outstanding at Ending	4 years
Weighted Average Remaining Contractual Term (in years), Exercisable	4 years
Aggregate Intrinsic Value, Outstanding at Beginning | $	$ 87,330
Aggregate Intrinsic Value, Forfeited and expired
Aggregate Intrinsic Value, Outstanding at Ending | $
Aggregate Intrinsic Value, Exercisable | $	$ 67,500

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details Textual) - USD ($)	9 Months Ended
	Dec. 31, 2019	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Noninterest expense directors fees	$ 2,110,000
Price difference between exercise price and quoted price	$ 0.0925	$ 0.10
Payment of employee salaries	22,536,856
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted vesting period of options	10 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted vesting period of options	3 years
Director [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares of common stock	585,417
Noninterest expense directors fees	$ 180,000
Shares for payment of directors fees outstanding	1,379,033
Accrued directors fees	$ 67,500
Cash payment made to director fees	22,500
Due to officers or stockholders	$ 60,000
Management [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payment of employee salaries	7,854,334
Chief Executive Officer [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payment of employee salaries	603,750
Chief Financial Officer [Member] | Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Payment of employee salaries	603,750

Concentrations and Credit Risk

Concentrations and Credit Risk (Details)	1 Months Ended	3 Months Ended		9 Months Ended
	Mar. 31, 2019Customers	Dec. 31, 2019Customers	Dec. 31, 2018Customers	Dec. 31, 2019SuppliersCustomers	Dec. 31, 2018SuppliersCustomers
Revenues [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		69.00%	58.00%	57.00%	63.00%
Number of customers		3	3	3	3
Revenues [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		12.00%	21.00%	24.00%	17.00%
Number of customers		3	3	3	3
Revenues [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		13.00%	7.00%	13.00%	16.00%
Number of customers		3	3	3	3
Revenues [Member] | Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				94.00%
Number of customers				3
Purchasing [Member] | Supplier One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				34.00%	40.00%
Number of suppliers | Suppliers				3	2
Purchasing [Member] | Supplier Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				25.00%	16.00%
Number of suppliers | Suppliers				3	2
Purchasing [Member] | Supplier Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				11.00%	15.00%
Number of suppliers | Suppliers				3	2
Purchasing [Member] | Supplier [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				85.00%	75.00%
Number of suppliers | Suppliers				8	7
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	38.00%			60.00%
Number of customers	4			3
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				22.00%
Number of customers				3
Accounts Receivable [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	19.00%			8.00%
Number of customers	4			3
Accounts Receivable [Member] | Customer [Member]
Concentration Risk [Line Items]
Concentration risk, percentage				90.00%
Number of customers				3
Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	34.00%
Number of customers	4
Accounts Receivable [Member] | Customer Four [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	4.00%
Number of customers	4

Segment Results (Details)

Segment Results (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Operating Income (Loss) by Segment
Operating Income (Loss) by Segment	$ 691,195	$ (2,637,130)	$ (911,042)	$ (7,148,496)
ANDA [Member]
Operating Income (Loss) by Segment
Operating Income (Loss) by Segment	2,431,906	(582,822)	2,538,560	(1,129,324)
NDA [Member]
Operating Income (Loss) by Segment
Operating Income (Loss) by Segment	135,500	(744,393)	407,245	(1,250,420)
Business Segment [Member]
Operating Income (Loss) by Segment
Operating Income (Loss) by Segment	$ 2,567,406	$ (1,327,215)	$ 2,945,805	$ (2,379,744)

Segment Results (Details 1)

Segment Results (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Operating income (loss) by segment	$ 691,195	$ (2,637,130)	$ (911,042)	$ (7,148,496)
Interest income	2,334	1,733	10,667	4,570
Depreciation and amortization expense	(323,368)	(321,164)	(986,001)	(891,390)
Loss from operations	(1,860,680)	(2,344,318)	(3,174,719)	(6,615,616)
Business Segment [Member]
Operating income (loss) by segment	2,567,406	(1,327,215)	2,945,805	(2,379,744)
Corporate unallocated costs	(739,790)	(667,002)	(1,740,579)	(3,111,346)
Interest income	2,334	1,733	10,667	4,570
Interest expense	(94,515)	(89,897)	(283,649)	(279,037)
Depreciation and amortization expense	(323,368)	(321,164)	(986,001)	(891,390)
Non-cash items	(213,052)	(321,749)	(532,267)	(766,016)
Change in fair value of derivative instruments – warrants	(3,059,695)	380,976	(2,590,695)	807,347
Loss from operations	$ (1,860,680)	$ (2,344,318)	$ (3,176,719)	$ (6,615,616)

Collaborative Agreement with _2

Collaborative Agreement with Epic Pharma LLC (Details) - USD ($)	1 Months Ended			9 Months Ended	12 Months Ended
	Jan. 31, 2016	Jun. 30, 2015	Jun. 04, 2015	Dec. 31, 2019	Mar. 31, 2016
2015 Epic License Agreement [Member]
Collaborative Agreement with Epic Pharma LLC (Textual)
Received payments totaling				$ 7,500,000
Additional due				$ 7,500,000
Non-refundable milestone	$ 2,500,000				$ 2,500,000
Description of license agreement expiration				The 2015 Epic License Agreement expires on June 4, 2020.
Collaborative Arrangement [Member]
Collaborative Agreement with Epic Pharma LLC (Textual)
Revenues recognition milestone method, description			The Company entered into the 2015 Epic License Agreement, which provides for the exclusive right to market, sell and distribute, by Epic Pharma LLC (“Epic”) of SequestOx™, an abuse deterrent opioid which employs the Company’s proprietary pharmacological abuse-deterrent technology. Epic will be responsible for payment of product development and pharmacovigilance costs, sales, and marketing of SequestOx™, and Elite will be responsible for the manufacture of the product. Under the 2015 Epic License Agreement, Epic will pay Elite non-refundable payments totaling $15 million, with such amount representing the cost of an exclusive license to ELI-200, the cost of developing the product and certain filings and a royalty based on an amount equal to 50% of profits derived from net product sales as defined in the 2015 Epic License Agreement. The initial term of the exclusive right to product development sales and distribution is five years (“Epic Exclusivity Period”); the license is renewable upon mutual agreement at the end of the initial term.
Elite received non-refundable payments totaling		$ 5,000,000

Related Party Transaction Agr_2

Related Party Transaction Agreements with Epic Pharma LLC (Details) - USD ($)	Jan. 14, 2016	Jan. 14, 2016	Jun. 04, 2015	Dec. 31, 2019
2015 Epic License Agreement [Member]
Related Party Transaction Agreements with Epic Pharma LLC (Textual)
Milestone payments	$ 2,500,000
Epic Generic Agreement [Member]
Related Party Transaction Agreements with Epic Pharma LLC (Textual)
Related party transaction amount				$ 1,800,000
Description of related party transactions				Elite was to receive $1.8 million, payable in increments that require the commercialization of all six exclusive products if the full amount is to be received, plus license fees equal to a percentage that is not less than 50% and not greater than 60% of profits achieved from commercial sales of the products, as defined in the Epic Generic Agreement. The Epic Generic Agreement expired on October 2, 2018 with Epic launching four of the six exclusive products and Elite collecting $1.0 million of the total $1.8 million fee.
2015 Epic License Agreement [Member]
Related Party Transaction Agreements with Epic Pharma LLC (Textual)
Milestone payments			$ 10,000,000
Description of related party transactions		The Company filed an NDA with the FDA for SequestOx™, thereby earning a $2.5 million milestone pursuant to the 2015 Epic License Agreement. The Company has received payment of this amount from Epic. An additional $7.5 million is due upon approval by the FDA of the NDA filed for SequestOx™. Please note that on July 15, 2016, the FDA issued a Complete Response Letter, or CRL, regarding the NDA. The CRL stated that the review cycle for the SequestOx™ NDA is complete and the application is not ready for approval in its present form. On December 21, 2016, the Company met with the FDA for an end-of-review meeting to discuss steps that it could take to obtain approval of SequestOx™. Based on this and the meeting minutes received from the FDA on January 23, 2017, the Company formulated a plan to address the issues cited by the FDA in the CRL, with such plan including, without limitation, modifying the SequestOx™ formulation, conducting bioequivalence and bioavailability fed and fasted studies, comparing the modified formulation to the original formulation. On July 7, 2017, the Company reported topline results from a pivotal bioequivalence fed study for SequestOx™. This study resulted in a mean Tmax of 4.6 hours, with a range of 0.5 hour to 12 hours and a mean Tmax of the comparator, Roxicodone® of 3.4 hours with a range of 0.5 hour to 12 hours. A key objective of this study was to determine if the reformulated SequestOx™ had a similar Tmax to the comparator when taken with a high fat meal. Based on these results, the Company will pause, not proceed, with the rest of the clinical trials, and seek clarity from the FDA before deciding on the next steps for immediate release SequestOx™. There can be no assurances of the success of any future clinical trials, or if such trials are successful, there can be no assurances that an intended future resubmission of the NDA product filing, if made, will be accepted by or receive marketing approval from the FDA, and accordingly, there can be no assurances that the Company will earn and receive the additional $7.5 million or future license fees.

Manufacturing, License and De_2

Manufacturing, License and Development Agreements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Manufacturing, License and Development Agreements (Textual)
Milestone method, description			The milestones, totaling $500k (with $405k already received), consist of amounts due upon the first shipment of each identified product, as follows: Phentermine 37.5mg tablets ($145k), Phentermine 15 & 30mg capsules ($45k), Hydromorphone 8mg ($125k), Naltrexone 50mg ($95k) and the balance of $95k due in relation to the first shipment of generic products which still require marketing authorizations from the FDA, and to which there can be no assurances of such marketing authorizations being granted and accordingly there can be no assurances that the Company will earn and receive these milestone amounts.
Revenue	$ 5,055,113	$ 2,693,966	$ 13,049,340	$ 6,224,713
Glenmark Alliance [Member]
Manufacturing, License and Development Agreements (Textual)
Milestone method, description			The Glenmark Alliance, provides for the manufacture by Elite and marketing by Glenmark of identified generic products under license from Elite. In addition to the purchase prices for the products, Elite will receive license fees well in excess of 50% of gross profits. Gross profit is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. Glenmark will have semi-exclusive marketing rights to the ANDA approved generic product, phendimetrazine 35mg tablets, and exclusive marketing rights to generic Methadone HCl. Collectively, the brand products and their generic equivalents had total annual sales of approximately $33.6 million in 2017, according to Quintiles IMS Health data. The Agreement has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Glenmark to terminate with regard to a product on at least three months' prior written notice if it determines to stop marketing and selling such product, and it permits Elite to terminate with regard to a product if at any time after the first twelvemonths from the first commercial sale, the average license fee paid by Glenmark for such product is less than $100,000 for a six-month sales period.
Lannett-SunGen Product Alliance [Member]
Manufacturing, License and Development Agreements (Textual)
Milestone method, description			Lannett-SunGen Product Alliance with Lannett Company Inc. ("Lannett"), Lannett will be the exclusive U.S. marketer and distributor for two generic products co-developed and co-owned by Elite and SunGen – Amphetamine IR Tablets and a second product which is an extended release CNS stimulant that is currently under review by the FDA. Elite will manufacture and Lannett will purchase the products from Elite and then sell and distribute them. In addition to the purchase prices for the products, Elite will receive license fees in excess of 50% of net profits, which will be shared equally with SunGen, pursuant to the SunGen Agreement. The Lannett-SunGen Product Alliance has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months' prior written notice, and it permits Elite or Lannett to terminate with regard to a product if at any time after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period. In addition to manufacturing fees and license fees, Lannett will also pay a milestone, of $750,000 upon commercial launch of the extended release CNS stimulant product that is currently under review by the FDA. This milestone payment will be shared equally by Elite and SunGen, pursuant to the SunGen Agreement.
Lannett-Elite Product Alliance [Member]
Manufacturing, License and Development Agreements (Textual)
Milestone method, description			Lannett-Elite Product Alliance, Lannett will be the exclusive U.S. marketer and distributor for Dantrolene Capsules. Elite will manufacture and Lannett will purchase Dantrolene Capsules from Elite and then sell and distribute them. In addition to the purchase prices for the products, Elite will receive license fees in excess of 50% of net profits. Net profits is defined as net sales less the price paid to Elite for the products, distribution fees (less than 10%) and shipping costs. The Lannett-Elite Product Alliance has an initial term of three years and automatically renews for one-year periods absent prior written notice of non-renewal. In addition to customary termination provisions, the Agreement permits Lannett to terminate with regard to a product on at least six months' prior written notice and it permits Elite or Lannett to terminate with regard to a product if at any time after the first twelve months from the first commercial sale, the average license fee paid by Lannett for such product is less than $300,000 for a six month sales period.
Precision Dose Agreement [Member]
Manufacturing, License and Development Agreements (Textual)
Milestone method, description			The Precision Dose Agreement provides for the marketing and distribution, by Precision Dose and its wholly owned subsidiary, TAGI Pharma, of Phentermine 37.5mg tablets (launched in April 2011), Phentermine 15mg capsules (launched in April 2013), Phentermine 30mg capsules (launched in April 2013), Hydromorphone 8mg tablets (launched in March 2012), Naltrexone 50mg tablets (launched in September 2013)
Revenue			$ 200,000

Related Party Agreements with_2

Related Party Agreements with Mikah Pharma LLC (Details) - Mikah [Member] - USD ($)	Dec. 31, 2019	Sep. 30, 2019	Jan. 31, 2019
Advance payment for purchase received	$ 480,000	$ 330,000	$ 150,000
Aggregate cost	452,348
Customer deposit	$ 55,653

Other Income - Proceeds from _2

Other Income - Proceeds from Sale of ANDAs (Details)	9 Months Ended
	Dec. 31, 2019USD ($)
Percocet [Member]
Total cash consideration	$ 300,000
Norco [Member]
Total cash consideration	$ 300,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	Feb. 04, 2020	Feb. 03, 2020
Subsequent Events (Textual)
Shares issued to Lincoln Park	5,337,102
Purchase of shares	5,265,484
Additional commitment shares	71,618
Total proceed from transaction	$ 517,037
Total cash consideration		$ 300,000
Carrying value for asset		$ 0